Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


Articles published in Ann Hematol

Retrieve available abstracts of 437 articles:
HTML format



Single Articles


    August 2021
  1. MIAN AA, Haberbosch I, Khamaisie H, Agbarya A, et al
    Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K).
    Ann Hematol. 2021;100:2023-2029.
    PubMed     Abstract available


    July 2021
  2. MI R, Chen L, Yang H, Zhang Y, et al
    Combined use of interferon alpha-1b, interleukin-2, and thalidomide to reverse the AML1-ETO fusion gene in acute myeloid leukemia.
    Ann Hematol. 2021 Jul 27. pii: 10.1007/s00277-021-04621.
    PubMed     Abstract available


  3. MATSUDA K, Jo T, Toyama K, Nakazaki K, et al
    Risk factors for early in-hospital death in patients who developed coagulopathy during induction therapy for acute promyelocytic leukemia: a nationwide analysis in Japan.
    Ann Hematol. 2021 Jul 26. pii: 10.1007/s00277-021-04620.
    PubMed     Abstract available


  4. ALRAWASHDH N, Sweasy J, Erstad B, McBride A, et al
    Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017).
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04600.
    PubMed     Abstract available


  5. ELNAIR R, Ellithi M, Kallam A, Shostrom V, et al
    Outcomes of Richter's transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database.
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04603.
    PubMed     Abstract available


  6. KONG J, Qin YZ, Zhao XS, Hou Y, et al
    Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04606.
    PubMed     Abstract available


  7. MICHAELIS S, Pichler A, Stelzer I, Schoffmann L, et al
    Aggressive NK-cell leukemia with hemophagocytosis in a Caucasian patient.
    Ann Hematol. 2021 Jul 16. pii: 10.1007/s00277-021-04585.
    PubMed    


  8. HARA R, Onizuka M, Kikkawa E, Shiraiwa S, et al
    Association between measurable residual disease kinetics and outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ann Hematol. 2021 Jul 11. pii: 10.1007/s00277-021-04587.
    PubMed     Abstract available


  9. BARZEGAR M, Farsani MA, Rafiee M, Amiri V, et al
    Acute promyelocytic leukemia derived extracellular vesicles conserve PML-RARalpha transcript from storage-inflicted degradation: a stable diagnosis tool in APL patients.
    Ann Hematol. 2021 Jul 8. pii: 10.1007/s00277-021-04579.
    PubMed     Abstract available


  10. TANIGAWA T, Sakurai M, Kato J, Mizuno K, et al
    Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2021 Jul 8. pii: 10.1007/s00277-021-04586.
    PubMed    


  11. GREIL R, Tedeschi A, Moreno C, Anz B, et al
    Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
    Ann Hematol. 2021;100:1733-1742.
    PubMed     Abstract available


  12. GADGEEL M, AlQanber B, Buck S, Taub JW, et al
    Aberrant myelomonocytic CD56 expression in Down syndrome is frequent and not associated with leukemogenesis.
    Ann Hematol. 2021;100:1695-1700.
    PubMed     Abstract available


    June 2021
  13. VIRK H, Rana S, Sharma P, Bose PL, et al
    Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.
    Ann Hematol. 2021 Jun 22. pii: 10.1007/s00277-021-04574.
    PubMed     Abstract available


  14. WYSOCKA-SLOWIK A, Gil L, Slebioda Z, Kregielczak A, et al
    Oral mucositis in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation in relation to the conditioning used prior to transplantation.
    Ann Hematol. 2021 Jun 12. pii: 10.1007/s00277-021-04568.
    PubMed     Abstract available


  15. KRECAK I, Cengic M, Skoric I, Nakic M, et al
    Concomitant autoimmune hemolytic anemia and pure red cell aplasia in a patient with chronic lymphocytic leukemia successfully treated with ibrutinib.
    Ann Hematol. 2021 Jun 10. pii: 10.1007/s00277-021-04570.
    PubMed    


  16. DOU X, Zheng F, Zhang L, Jin J, et al
    Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study.
    Ann Hematol. 2021 Jun 5. pii: 10.1007/s00277-021-04544.
    PubMed     Abstract available


  17. AL-SARAYFI D, Meeuwes FO, Munnink TO, Plattel W, et al
    Successful treatment of hairy cell leukemia variant with obinutuzumab.
    Ann Hematol. 2021 Jun 4. pii: 10.1007/s00277-021-04559.
    PubMed    


  18. LARIBI K, Sobh M, Ghez D, Baugier de Materre A, et al
    Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review.
    Ann Hematol. 2021;100:1359-1376.
    PubMed     Abstract available


  19. ZENG Z, Ly C, Daver N, Cortes J, et al
    High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells.
    Ann Hematol. 2021;100:1485-1496.
    PubMed     Abstract available


    May 2021
  20. HEUSER M, Smith BD, Fiedler W, Sekeres MA, et al
    Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
    Ann Hematol. 2021 May 12. pii: 10.1007/s00277-021-04545.
    PubMed    


  21. KONG J, Chen N, Li M, Zhang J, et al
    Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.
    Ann Hematol. 2021 May 6. pii: 10.1007/s00277-021-04530.
    PubMed    


  22. DEVOS T, Havelange V, Theunissen K, Meers S, et al
    Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
    Ann Hematol. 2021 May 4. pii: 10.1007/s00277-021-04507.
    PubMed     Abstract available


  23. GONZALEZ JS, Perusini MA, Basquiera AL, Alfonso G, et al
    Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients.
    Ann Hematol. 2021 May 1. pii: 10.1007/s00277-021-04539.
    PubMed     Abstract available


  24. SALAMONOWICZ-BODZIOCH M, Fraczkiewicz J, Czyzewski K, Zajac-Spychala O, et al
    Prospective analysis of BKV hemorrhagic cystitis in children and adolescents undergoing hematopoietic cell transplantation.
    Ann Hematol. 2021;100:1283-1293.
    PubMed     Abstract available


  25. TANG KHK, Ip AHW, Kwong YL
    Clonal derivation of sequential seminoma and acute megakaryoblastic leukaemia.
    Ann Hematol. 2021;100:1337-1339.
    PubMed    


  26. HORIUCHI M, Yoshida M, Yamasaki K, Sakagami R, et al
    Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion.
    Ann Hematol. 2021;100:1329-1331.
    PubMed    


  27. BERNARDI S, Zanaglio C, Farina M, Polverelli N, et al
    dsDNA from extracellular vesicles (EVs) in adult AML.
    Ann Hematol. 2021;100:1355-1356.
    PubMed    


    April 2021
  28. MARTINEZ SANCHEZ MP, Megias-Vericat JE, Rodriguez-Veiga R, Vives S, et al
    A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
    Ann Hematol. 2021 Apr 29. pii: 10.1007/s00277-021-04542.
    PubMed     Abstract available


  29. ZHAO H, Sun J, Yan L, Jin B, et al
    Tissue factor-bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study.
    Ann Hematol. 2021 Apr 24. pii: 10.1007/s00277-021-04533.
    PubMed     Abstract available


  30. KE P, Zhang X, Liu S, Zhu Q, et al
    The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen.
    Ann Hematol. 2021 Apr 22. pii: 10.1007/s00277-021-04528.
    PubMed     Abstract available


  31. ONAKA T, Kato-Ogura A, Otsuka Y, Iwai F, et al
    A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer.
    Ann Hematol. 2021 Apr 12. pii: 10.1007/s00277-021-04516.
    PubMed    


  32. OWATTANAPANICH W, Herzig J, Jahn N, Panina E, et al
    Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique.
    Ann Hematol. 2021 Apr 10. pii: 10.1007/s00277-021-04513.
    PubMed     Abstract available


  33. QIAN Y, Chen Y, Li X
    CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
    Ann Hematol. 2021 Apr 6. pii: 10.1007/s00277-021-04491.
    PubMed     Abstract available


  34. MODI D, Singh V, Kim S, Ayash L, et al
    Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
    Ann Hematol. 2021;100:969-978.
    PubMed     Abstract available


  35. HU L, Charwudzi A, Li Q, Zhu W, et al
    Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis.
    Ann Hematol. 2021;100:1003-1012.
    PubMed     Abstract available


  36. SCHULER E, Wagner-Drouet EM, Ajib S, Bug G, et al
    Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Ann Hematol. 2021;100:959-968.
    PubMed     Abstract available


  37. RETTIG AR, Ihorst G, Bertz H, Lubbert M, et al
    Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis.
    Ann Hematol. 2021 Apr 1. pii: 10.1007/s00277-021-04494.
    PubMed     Abstract available


    March 2021
  38. LEOTTA S, Markovic U, Pirosa MC, Stella S, et al
    The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study.
    Ann Hematol. 2021 Mar 28. pii: 10.1007/s00277-021-04504.
    PubMed     Abstract available


  39. HEUSER M, Smith BD, Fiedler W, Sekeres MA, et al
    Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
    Ann Hematol. 2021 Mar 19. pii: 10.1007/s00277-021-04465.
    PubMed     Abstract available


  40. SHOUMARIYEH K, Jung J, Rassner M, Dold SM, et al
    Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.
    Ann Hematol. 2021 Mar 13. pii: 10.1007/s00277-021-04490.
    PubMed    


  41. LIU J, Zhang XH, Xu LP, Wang Y, et al
    Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2021 Mar 13. pii: 10.1007/s00277-021-04488.
    PubMed     Abstract available


  42. BALLO O, Eladly F, Buttner S, Stratmann JA, et al
    Acute kidney injury adversely affects the clinical course of acute myeloid leukemia patients undergoing induction chemotherapy.
    Ann Hematol. 2021 Mar 11. pii: 10.1007/s00277-021-04482.
    PubMed     Abstract available


  43. SCALZULLI E, Caocci G, Efficace F, Rizzo L, et al
    Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.
    Ann Hematol. 2021 Mar 7. pii: 10.1007/s00277-021-04477.
    PubMed     Abstract available


  44. LI T, Chen H, Zhang Y, Zeng Y, et al
    Very rare lineage switch from acute myeloid leukemia with BCR-ABL1 to B-lymphoblastic leukemia.
    Ann Hematol. 2021 Mar 5. pii: 10.1007/s00277-021-04483.
    PubMed    


  45. ZUCENKA A, Maneikis K, Pugaciute B, Ringeleviciute U, et al
    Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients.
    Ann Hematol. 2021 Mar 4. pii: 10.1007/s00277-021-04471.
    PubMed     Abstract available


  46. BRUNE MM, Stussi G, Lundberg P, Vela V, et al
    Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort.
    Ann Hematol. 2021 Mar 2. pii: 10.1007/s00277-021-04467.
    PubMed     Abstract available


  47. STEINER N, Brunelli L, Hetzenauer G, Lindner B, et al
    Early autologous and allogeneic peripheral blood stem cell transplantation for adult patients with acute B and T cell precursor neoplasms: a 12-year single center experience.
    Ann Hematol. 2021;100:809-816.
    PubMed     Abstract available


  48. YU WJ, Sun YQ, Han TT, Ye PP, et al
    Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: a single center retrospective study.
    Ann Hematol. 2021;100:799-808.
    PubMed     Abstract available


  49. BOSCH F, Navarro B, Crespo M, Alcoceba M, et al
    Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative.
    Ann Hematol. 2021;100:825-830.
    PubMed     Abstract available


  50. LAHLIMI FZ, Tazi I
    A rare cause of respiratory failure in acute myeloid leukaemia patient.
    Ann Hematol. 2021;100:831-832.
    PubMed    


    February 2021
  51. ISOBE M, Konuma T, Masuko M, Uchida N, et al
    Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan.
    Ann Hematol. 2021 Feb 23. pii: 10.1007/s00277-021-04464.
    PubMed     Abstract available


  52. OLIVA S, De Paoli L, Ruggeri M, Caltagirone S, et al
    A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
    Ann Hematol. 2021;100:437-443.
    PubMed     Abstract available


  53. WANG Z, Liu W, Wang M, Li Y, et al
    Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis.
    Ann Hematol. 2021;100:465-479.
    PubMed     Abstract available


  54. GHOSH S, Chakraborty M, Samanta S, Sinha N, et al
    Analysis of blood stream infections, antibiograms and clinical outcomes in haematological patients with febrile neutropenia: data from a tertiary care haematology institute in India.
    Ann Hematol. 2021;100:395-403.
    PubMed     Abstract available


  55. ENGEL NW, Reinert J, Borchert NM, Panagiota V, et al
    Newly diagnosed isolated myeloid sarcoma-paired NGS panel analysis of extramedullary tumor and bone marrow.
    Ann Hematol. 2021;100:499-503.
    PubMed     Abstract available


  56. AKIMOTO M, Sakurai A, Nishiyama-Fujita Y, Ito C, et al
    The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.
    Ann Hematol. 2021 Feb 1. pii: 10.1007/s00277-021-04440.
    PubMed     Abstract available


    January 2021
  57. BOUCLET F, Calleja A, Dilhuydy MS, Veronese L, et al
    Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
    Ann Hematol. 2021 Jan 25. pii: 10.1007/s00277-021-04419.
    PubMed     Abstract available


  58. DUAN W, Liu X, Zhao X, Jia J, et al
    Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.
    Ann Hematol. 2021 Jan 20. pii: 10.1007/s00277-021-04432.
    PubMed     Abstract available


  59. TONG J, Zhang L, Liu H, Xu X, et al
    Umbilical cord blood transplantation can overcome the poor prognosis of KMT2A-MLLT3 acute myeloid leukemia and can lead to good GVHD-free/relapse-free survival.
    Ann Hematol. 2021 Jan 20. pii: 10.1007/s00277-021-04413.
    PubMed     Abstract available


  60. VOIGT M, Sinn K, Malouhi A, Gecks T, et al
    HHV-6 encephalitis in a non-transplanted adult acute myeloid leukemia patient.
    Ann Hematol. 2021 Jan 14. pii: 10.1007/s00277-021-04409.
    PubMed    


  61. AMIT O, On YB, Perez G, Shargian-Alon L, et al
    Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial.
    Ann Hematol. 2021 Jan 13. pii: 10.1007/s00277-021-04398.
    PubMed     Abstract available


  62. LIAO PW, Wang RC, Chen TC, Teng CJ, et al
    Venetoclax-induced panniculitis in an acute myeloid leukemia patient.
    Ann Hematol. 2021 Jan 13. pii: 10.1007/s00277-020-04372.
    PubMed    


  63. SCHLAWECK S, Brossart P, Heine A
    Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah's Witness patient.
    Ann Hematol. 2021 Jan 12. pii: 10.1007/s00277-021-04403.
    PubMed    


  64. KERUAKOUS AR, Balakrishna P, Schmidt SA, Autry MT, et al
    Genomic profiling is a supplemental diagnostic and therapeutic modality for hairy cell leukemia variant.
    Ann Hematol. 2021 Jan 12. pii: 10.1007/s00277-021-04408.
    PubMed    


  65. MARTIN-MORO F, Garcia-Cosio M, Marquet-Palomanes J, Lopez-Gutierrez M, et al
    Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib.
    Ann Hematol. 2021 Jan 9. pii: 10.1007/s00277-021-04393.
    PubMed    


  66. BRECCIA M, Celant S, Olimpieri PP, Olimpieri OM, et al
    Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA).
    Ann Hematol. 2021 Jan 7. pii: 10.1007/s00277-021-04406.
    PubMed     Abstract available


  67. MA YR, Xu LP, Zhang XH, Liu KY, et al
    Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblings.
    Ann Hematol. 2021 Jan 7. pii: 10.1007/s00277-020-04359.
    PubMed     Abstract available


  68. CAOCCI G, Mulas O, Capodanno I, Bonifacio M, et al
    Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
    Ann Hematol. 2021 Jan 3. pii: 10.1007/s00277-020-04392.
    PubMed     Abstract available


  69. CHEN Q, Zhu XL, Zhao X, Liu X, et al
    Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Ann Hematol. 2021 Jan 2. pii: 10.1007/s00277-020-04380.
    PubMed     Abstract available


  70. LIU J, Shen L, Huang H, Gao X, et al
    A rare case of donor-derived promyelocytic sarcoma in a kidney transplant recipient.
    Ann Hematol. 2021;100:295-296.
    PubMed    


    December 2020
  71. ANGENENDT L, Hilgefort I, Mikesch JH, Schluter B, et al
    Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Ann Hematol. 2020 Dec 19. pii: 10.1007/s00277-020-04382.
    PubMed     Abstract available


  72. YAMASAKI S, Mori J, Kanda J, Imahashi N, et al
    Effect of allogeneic HCT from unrelated donors in AML patients with intermediate- or poor-risk cytogenetics: a retrospective study from the Japanese Society for HCT.
    Ann Hematol. 2020;99:2927-2937.
    PubMed     Abstract available


  73. CHEN H, Qin Y, Yang J, Liu P, et al
    Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma.
    Ann Hematol. 2020;99:2847-2857.
    PubMed     Abstract available


    November 2020
  74. FUJI S, Kida S, Nakata K, Morishima T, et al
    Correction to: Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma-not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Regist
    Ann Hematol. 2020 Nov 28. pii: 10.1007/s00277-020-04352.
    PubMed     Abstract available


  75. LU Y, Zhao YL, Zhang JP, Xiong M, et al
    Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a s
    Ann Hematol. 2020 Nov 24. pii: 10.1007/s00277-020-04355.
    PubMed     Abstract available


  76. RASEKH EO, Osman R, Ibraheem D, Madney Y, et al
    Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients.
    Ann Hematol. 2020 Nov 23. pii: 10.1007/s00277-020-04354.
    PubMed     Abstract available


  77. WANG YH, Lin CC, Hsu CL, Hung SY, et al
    Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125.
    Ann Hematol. 2020 Nov 23. pii: 10.1007/s00277-020-04358.
    PubMed     Abstract available


  78. ROBAK E, Jesionek-Kupnicka D, Robak T
    Skin changes in hairy cell leukemia.
    Ann Hematol. 2020 Nov 20. pii: 10.1007/s00277-020-04349.
    PubMed     Abstract available


  79. ZAPPASODI P, Brociner M, Merati G, Nizzoli ME, et al
    Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
    Ann Hematol. 2020 Nov 11. pii: 10.1007/s00277-020-04333.
    PubMed    


  80. MORI Y, Sasaki K, Ito Y, Kuriyama T, et al
    Outcome predictors after retransplantation in relapsed acute lymphoblastic leukemia: a multicenter, retrospective study.
    Ann Hematol. 2020 Nov 5. pii: 10.1007/s00277-020-04310.
    PubMed     Abstract available


    October 2020
  81. YUAN XL, Tan YM, Shi JM, Zhao YM, et al
    Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2020 Oct 31. pii: 10.1007/s00277-020-04326.
    PubMed     Abstract available


  82. FUJI S, Kida S, Nakata K, Morishima T, et al
    Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma-not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Registry.
    Ann Hematol. 2020 Oct 21. pii: 10.1007/s00277-020-04308.
    PubMed     Abstract available


  83. CORNELISSEN LL, Kreuger AL, Caram-Deelder C, Middelburg RA, et al
    Thrombocytopenia and the effect of platelet transfusions on the occurrence of intracranial hemorrhage in patients with acute leukemia - a nested case-control study.
    Ann Hematol. 2020 Oct 17. pii: 10.1007/s00277-020-04298.
    PubMed     Abstract available


  84. PHUKAN A, Mandal PK, Dolai TK
    Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India.
    Ann Hematol. 2020 Oct 6. pii: 10.1007/s00277-020-04289.
    PubMed     Abstract available


  85. TAVARES M, Chacim S, Mariz JM
    Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Ann Hematol. 2020 Oct 1. pii: 10.1007/s00277-020-04291.
    PubMed    


  86. MOORE DC, Nelson V, Muslimani A
    Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma.
    Ann Hematol. 2020 Oct 1. pii: 10.1007/s00277-020-04285.
    PubMed    


  87. LU Y, Zhao YL, Zhang JP, Xiong M, et al
    Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
    Ann Hematol. 2020 Oct 1. pii: 10.1007/s00277-020-04283.
    PubMed     Abstract available


  88. JENTZSCH M, Bill M, Grimm J, Brauer D, et al
    Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML.
    Ann Hematol. 2020;99:2417-2427.
    PubMed     Abstract available


  89. VIARDOT A, Locatelli F, Stieglmaier J, Zaman F, et al
    Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
    Ann Hematol. 2020;99:2215-2229.
    PubMed     Abstract available


  90. KAWADA K, Ohta T, Fukuda H, Hayashi T, et al
    Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis.
    Ann Hematol. 2020;99:2429-2436.
    PubMed     Abstract available


  91. BENETATOS L, Benetatou A, Vartholomatos G
    Long non-coding RNAs and MYC association in hematological malignancies.
    Ann Hematol. 2020;99:2231-2242.
    PubMed     Abstract available


  92. ZHANG L, Wang M, Wang Z, Zeng Z, et al
    Identification of a novel ETV6 truncated fusion gene in myeloproliferative neoplasm, unclassifiable with t(4;12)(q12;p13).
    Ann Hematol. 2020;99:2445-2447.
    PubMed    


  93. TEY A, Mohan B, Cheah R, Dendle C, et al
    Disseminated Lomentospora prolificans infection in a patient on idelalisib-rituximab therapy for relapsed chronic lymphocytic leukaemia.
    Ann Hematol. 2020;99:2455-2456.
    PubMed    


    September 2020
  94. RAMOS-PENAFIEL C, Olarte-Carrillo I, Maldonado RC, de la Cruz Rosas A, et al
    Association of three factors (ABCB1 gene expression, steroid response, early response at day + 8) on the response to induction in patients with acute lymphoblastic leukemia.
    Ann Hematol. 2020 Sep 27. pii: 10.1007/s00277-020-04277.
    PubMed     Abstract available


  95. JING Y, Li YF, Wan H, Liu DH, et al
    Detection of EP300-ZNF384 fusion in patients with acute lymphoblastic leukemia using RNA fusion gene panel sequencing.
    Ann Hematol. 2020 Sep 26. pii: 10.1007/s00277-020-04251.
    PubMed     Abstract available


  96. BALLO O, Kreisel EM, Eladly F, Brunnberg U, et al
    Use of carbapenems and glycopeptides increases risk for Clostridioides difficile infections in acute myeloid leukemia patients undergoing intensive induction chemotherapy.
    Ann Hematol. 2020 Sep 24. pii: 10.1007/s00277-020-04274.
    PubMed     Abstract available


  97. WEI H, Kuang P, Liu T
    Comparative study on allogeneic with autologous hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the era of TKIs: a systematic review and meta-analysis.
    Ann Hematol. 2020 Sep 22. pii: 10.1007/s00277-020-04258.
    PubMed     Abstract available


  98. ZHAO Y, Rehder C, Wang E
    Circulating blastoid cells: acute leukemia, prolymphocytic leukemia, or something else?
    Ann Hematol. 2020 Sep 15. pii: 10.1007/s00277-020-04270.
    PubMed    


  99. SHI X, Jiang Q, You H, Liu Y, et al
    Rare synchronous co-existence of acute myeloid leukemia and hairy cell leukemia in a same patient.
    Ann Hematol. 2020 Sep 14. pii: 10.1007/s00277-020-04272.
    PubMed    


  100. SHARGIAN-ALON L, Wolach O, Rozovski U, Yahav D, et al
    Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia.
    Ann Hematol. 2020 Sep 6. pii: 10.1007/s00277-020-04232.
    PubMed     Abstract available


  101. YU J, Ge X, Luo Y, Shi J, et al
    Incidence, risk factors and outcome of extramedullary relapse after allogeneic hematopoietic stem cell transplantation in patients with adult acute lymphoblastic leukemia.
    Ann Hematol. 2020 Sep 5. pii: 10.1007/s00277-020-04199.
    PubMed     Abstract available


  102. MINAMIGUCHI H, Fujita H, Atsuta Y, Asou N, et al
    Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia.
    Ann Hematol. 2020 Sep 2. pii: 10.1007/s00277-020-04245.
    PubMed     Abstract available


  103. DUONG VH, Begna KH, Kashanian S, Sweet K, et al
    Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study.
    Ann Hematol. 2020;99:2119-2124.
    PubMed     Abstract available


  104. KOLB HJ, Schmid C
    The FLAMSA concept-past and future.
    Ann Hematol. 2020;99:1979-1988.
    PubMed     Abstract available


  105. VALE CA, Egan PC, Ingham R, Farmakiotis D, et al
    Antibiotic use during cytarabine consolidation in acute myeloid leukemia.
    Ann Hematol. 2020 Sep 1. pii: 10.1007/s00277-020-04238.
    PubMed     Abstract available


    August 2020
  106. ICHIKAWA S, Fujiwara T, Saito K, Fukuhara N, et al
    A novel case of gammadelta T cell leukemia with recurrent genetic abnormalities accompanied by agranulocytosis.
    Ann Hematol. 2020 Aug 31. pii: 10.1007/s00277-020-04241.
    PubMed    


  107. LIU W, Burger JA, Xu J, Tang Z, et al
    LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
    Ann Hematol. 2020 Aug 24. pii: 10.1007/s00277-020-04223.
    PubMed     Abstract available


  108. WULLENKORD R, Reicherts C, Mikesch JH, Marx J, et al
    Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.
    Ann Hematol. 2020 Aug 22. pii: 10.1007/s00277-020-04227.
    PubMed    


  109. PEPE S, Scalzulli E, Colafigli G, Di Prima A, et al
    Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
    Ann Hematol. 2020 Aug 19. pii: 10.1007/s00277-020-04217.
    PubMed     Abstract available


  110. TACHIBANA T, Najima Y, Akahoshi Y, Hirabayashi S, et al
    The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2020 Aug 15. pii: 10.1007/s00277-020-04212.
    PubMed     Abstract available


  111. LE BOURGEOIS A, Labopin M, Marcais A, de Latour RP, et al
    Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFG
    Ann Hematol. 2020;99:1855-1862.
    PubMed     Abstract available


  112. KARA ALI R, Surme S, Balkan II, Salihoglu A, et al
    An eleven-year cohort of bloodstream infections in 552 febrile neutropenic patients: resistance profiles of Gram-negative bacteria as a predictor of mortality.
    Ann Hematol. 2020;99:1925-1932.
    PubMed     Abstract available


  113. FLORES V, Miranda R, Merino L, Gonzalez C, et al
    SARS-CoV-2 infection in children with febrile neutropenia.
    Ann Hematol. 2020;99:1941-1942.
    PubMed    


    July 2020
  114. BETTELLI F, Giusti D, Morselli M, Colaci E, et al
    Epidemiology and clinical outcomes of latent tuberculosis infection in adults affected with acute leukemia or aplastic anemia: a retrospective single-center study.
    Ann Hematol. 2020 Jul 23. pii: 10.1007/s00277-020-04191.
    PubMed    


  115. SHAHSWAR R, Beutel G, Gabdoulline R, Koenecke C, et al
    Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up.
    Ann Hematol. 2020 Jul 23. pii: 10.1007/s00277-020-04181.
    PubMed    


  116. MEGIAS-VERICAT JE, Solana-Altabella A, Ballesta-Lopez O, Martinez-Cuadron D, et al
    Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.
    Ann Hematol. 2020 Jul 18. pii: 10.1007/s00277-020-04186.
    PubMed     Abstract available


  117. IKEDA Y, Yamanouchi J, Takenaka K
    Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation.
    Ann Hematol. 2020 Jul 16. pii: 10.1007/s00277-020-04185.
    PubMed    


  118. CHENG FM, Tien JZ, Chen TT, Yeh SP, et al
    Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.
    Ann Hematol. 2020 Jul 3. pii: 10.1007/s00277-020-04168.
    PubMed    


  119. ZANELLI M, Ricci S, Zizzo M, Sanguedolce F, et al
    Bone marrow coexistence of chronic lymphocytic leukemia and Langerhans cell sarcoma.
    Ann Hematol. 2020 Jul 3. pii: 10.1007/s00277-020-04167.
    PubMed    


  120. KUNADT D, Dransfeld C, Dill C, Schmiedgen M, et al
    Multidrug-related protein 1 (MRP1) polymorphisms rs129081, rs212090, and rs212091 predict survival in normal karyotype acute myeloid leukemia.
    Ann Hematol. 2020 Jul 3. pii: 10.1007/s00277-020-04163.
    PubMed     Abstract available


  121. CHENG Z, Luo Y, Zhang Y, Wang Y, et al
    A novel NAP1L4/NUTM1 fusion arising from translocation t(11;15)(p15;q12) in a myeloid neoplasm with eosinophilia and rearrangement of PDGFRA highlights an unusual clinical feature and therapeutic reaction.
    Ann Hematol. 2020;99:1561-1564.
    PubMed     Abstract available


  122. KOVAL SV, Gluzman DF, Sklyarenko LM, Ivanivska TS, et al
    Hematological malignancies in Ukraine in post-Chernobyl era: sources of data and their preliminary analysis.
    Ann Hematol. 2020;99:1543-1550.
    PubMed     Abstract available


    June 2020
  123. HINZE A, Rinke J, Hochhaus A, Ernst T, et al
    Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation.
    Ann Hematol. 2020 Jun 23. pii: 10.1007/s00277-020-04152.
    PubMed    


  124. LI Z, Lai Y, Zhang X, Xu L, et al
    Monosomal karyotype is associated with poor outcomes in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia receiving chemotherapy but not allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2020 Jun 23. pii: 10.1007/s00277-020-04155.
    PubMed     Abstract available


  125. MARTINS F, Kruszewski M, Scarpelli I, Schoumans J, et al
    Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia.
    Ann Hematol. 2020 Jun 16. pii: 10.1007/s00277-020-04114.
    PubMed     Abstract available


  126. HOCHMAN MJ, Martin DB
    Coincidence of autoimmune hemolytic anemia and pure red cell aplasia in a patient with CLL.
    Ann Hematol. 2020 Jun 16. pii: 10.1007/s00277-020-04091.
    PubMed    


  127. ROBAK P, Jesionek-Kupnicka D, Kupnicki P, Polliack A, et al
    Multifocal osteolytic lesions in hairy cell leukemia-the importance of PET/CT in diagnosis and assessment.
    Ann Hematol. 2020 Jun 12. pii: 10.1007/s00277-020-04121.
    PubMed    


  128. STEMLER J, Koehler P, Maurer C, Muller C, et al
    Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma.
    Ann Hematol. 2020 Jun 8. pii: 10.1007/s00277-020-04107.
    PubMed     Abstract available


  129. YANAGISAWA H, Mizuta S, Kawabata H, Fujimoto S, et al
    Faggot cells in acute myeloid leukemia with t(7;11)(p15;p15) and NUP98-HOXA9 fusion.
    Ann Hematol. 2020 Jun 8. pii: 10.1007/s00277-020-04122.
    PubMed    


  130. BECKER H, Pfeifer D, Ihorst G, Pantic M, et al
    Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
    Ann Hematol. 2020 Jun 6. pii: 10.1007/s00277-020-04082.
    PubMed     Abstract available


  131. ARCHIBALD WJ, Rabe KG, Kabat BF, Herrmann J, et al
    Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
    Ann Hematol. 2020 Jun 1. pii: 10.1007/s00277-020-04094.
    PubMed     Abstract available


    May 2020
  132. MULAS O, Caocci G, Stagno F, Bonifacio M, et al
    Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
    Ann Hematol. 2020 May 30. pii: 10.1007/s00277-020-04102.
    PubMed     Abstract available


  133. SCALZULLI E, Colafigli G, Latagliata R, Pepe S, et al
    Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients.
    Ann Hematol. 2020 May 28. pii: 10.1007/s00277-020-04096.
    PubMed     Abstract available


  134. CHEN Q, Zhao X, Fu HX, Chen YH, et al
    Comparison of central nervous system relapse outcomes following haploidentical vs identical-sibling transplant for acute lymphoblastic leukemia.
    Ann Hematol. 2020 May 26. pii: 10.1007/s00277-020-04080.
    PubMed     Abstract available


  135. MAAKARON JE, Ozga MP, Mannis GN, Pulley W, et al
    Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia.
    Ann Hematol. 2020 May 6. pii: 10.1007/s00277-020-04054.
    PubMed    


  136. YANADA M, Takami A, Yamasaki S, Arai Y, et al
    Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century.
    Ann Hematol. 2020 May 4. pii: 10.1007/s00277-020-04051.
    PubMed     Abstract available


    April 2020
  137. HELBIG G, Koclega A, Wieczorkiewicz-Kabut A, Wozniczka K, et al
    Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation.
    Ann Hematol. 2020 Apr 24. pii: 10.1007/s00277-020-04026.
    PubMed     Abstract available


  138. HORISAWA Y, Kondo T, Hishizawa M, Yamashita K, et al
    A case of allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia after treatment with daratumumab.
    Ann Hematol. 2020 Apr 21. pii: 10.1007/s00277-020-04029.
    PubMed    


  139. BRUMMENDORF TH, Gambacorti-Passerini C, Bushmakin AG, Cappelleri JC, et al
    Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia.
    Ann Hematol. 2020 Apr 19. pii: 10.1007/s00277-020-04018.
    PubMed     Abstract available


  140. GAO M, Zhao X
    Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia.
    Ann Hematol. 2020 Apr 19. pii: 10.1007/s00277-020-04037.
    PubMed    


  141. GUPTA C, Kaulfuss S, Gorlich K, Othman B, et al
    Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia.
    Ann Hematol. 2020 Apr 15. pii: 10.1007/s00277-020-04001.
    PubMed    


  142. MIN GJ, Cho BS, Park SS, Park S, et al
    Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death.
    Ann Hematol. 2020 Apr 8. pii: 10.1007/s00277-020-04010.
    PubMed     Abstract available


  143. SPIESS B, Kleiner H, Flach J, Fabarius A, et al
    Separase activity distribution can be a marker of major molecular response and proliferation of CD34(+) cells in TKI-treated chronic myeloid leukemia patients.
    Ann Hematol. 2020 Apr 6. pii: 10.1007/s00277-020-04007.
    PubMed     Abstract available


  144. APEL A, Ofran Y, Wolach O, Shimony S, et al
    Safety and efficacy of blinatumomab: a real world data.
    Ann Hematol. 2020;99:835-838.
    PubMed     Abstract available


  145. BUSSAGLIA E, Pratcorona M, Carricondo M, Sansegundo L, et al
    Application of a digital PCR method for WT1 to myeloid neoplasms in CR and deep ELN WT1 molecular response (< 10 copies).
    Ann Hematol. 2020;99:765-772.
    PubMed     Abstract available


    March 2020
  146. OZBAGCIVAN O, Akarsu S, Nazli EC, Lebe B, et al
    Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia.
    Ann Hematol. 2020 Mar 27. pii: 10.1007/s00277-020-04009.
    PubMed    


  147. VAN DER STRATEN L, Kater AP, Doorduijn JK, van den Broek EC, et al
    Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia.
    Ann Hematol. 2020 Mar 19. pii: 10.1007/s00277-020-03994.
    PubMed     Abstract available


  148. PERINGETH G, Sundaram S, Bogner P, Conroy E, et al
    Successful use of venetoclax for treatment of eosinophilic dermatosis of myeloproliferative disease in a patient with chronic lymphocytic leukemia.
    Ann Hematol. 2020 Mar 19. pii: 10.1007/s00277-020-03991.
    PubMed    


  149. ERNST P, Engmann B, Frietsch JJ, Schnetzke U, et al
    A 19-year-old patient with atypical chronic myeloid leukemia.
    Ann Hematol. 2020 Mar 19. pii: 10.1007/s00277-020-03992.
    PubMed    


  150. MASSAIU R, Longu F, Podda L, Mura F, et al
    Rectal involvement in pre-early T acute lymphoblastic leukemia.
    Ann Hematol. 2020 Mar 16. pii: 10.1007/s00277-020-03998.
    PubMed    


  151. SORIGUE M, Espasa A, Zamora L, Junca J, et al
    Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia.
    Ann Hematol. 2020 Mar 13. pii: 10.1007/s00277-020-03997.
    PubMed    


  152. TAKEUCHI M, Miyoshi H, Nakashima K, Kawamoto K, et al
    Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma.
    Ann Hematol. 2020 Mar 10. pii: 10.1007/s00277-020-03967.
    PubMed     Abstract available


  153. XIE W, Tang G, Wang E, Kim Y, et al
    t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?
    Ann Hematol. 2020;99:487-500.
    PubMed     Abstract available


  154. PABST G, Lind K, Graf R, Zebisch A, et al
    TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model.
    Ann Hematol. 2020;99:653-655.
    PubMed    


  155. MARTIN I, Navarro B, Serrano A, Villamon E, et al
    Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine.
    Ann Hematol. 2020;99:527-537.
    PubMed     Abstract available


  156. ALKHARABSHEH O, Patnaik MM, Gangat N, Begna KH, et al
    Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system.
    Ann Hematol. 2020;99:513-518.
    PubMed     Abstract available


  157. ANZEJ DOMA S, Skerget M, Pajic T, Sever M, et al
    Improved survival of AML patients by addition of cladribine to standard induction chemotherapy.
    Ann Hematol. 2020;99:519-525.
    PubMed     Abstract available


  158. HEITMANN JS, Hagelstein I, Hinterleitner C, Roerden M, et al
    Identification of CD318 (CDCP1) as novel prognostic marker in AML.
    Ann Hematol. 2020;99:477-486.
    PubMed     Abstract available


  159. KONTOPOULOU E, Strachan S, Reinhardt K, Kunz F, et al
    Evaluation of dsDNA from extracellular vesicles (EVs) in pediatric AML diagnostics.
    Ann Hematol. 2020;99:459-475.
    PubMed     Abstract available


    February 2020
  160. TING S, Mixue X, Lixia Z, Xueying L, et al
    T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
    Ann Hematol. 2020 Feb 27. pii: 10.1007/s00277-020-03949.
    PubMed     Abstract available


  161. BOUCHACOURT B, Hospital MA, Zemmour C, Rey J, et al
    Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome.
    Ann Hematol. 2020 Feb 22. pii: 10.1007/s00277-020-03922.
    PubMed     Abstract available


  162. LUBER V, Lutz M, Thiede C, Haferlach C, et al
    Donor-cell leukemia with novel genetic features 2 years after sex-mismatched T cell-depleted haploidentical stem cell transplantation.
    Ann Hematol. 2020 Feb 22. pii: 10.1007/s00277-020-03905.
    PubMed    


  163. SCHIECK M, Lentes J, Thomay K, Hofmann W, et al
    Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia.
    Ann Hematol. 2020 Feb 20. pii: 10.1007/s00277-020-03953.
    PubMed     Abstract available


  164. GRUHN B, Brodt G, Wittig S, Ernst T, et al
    Molecular remission using three monoclonal antibodies followed by allogeneic bone marrow transplantation in an infant with refractory ALL.
    Ann Hematol. 2020 Feb 18. pii: 10.1007/s00277-020-03957.
    PubMed    


  165. HAN Q, Tao L, Jiang X, Chen H, et al
    An atypical chronic neutrophilic leukemia patient harboring ASXL1 and NRAS mutations associated with monoclonal plasma cell dyscrasia presenting as hemopericardium.
    Ann Hematol. 2020 Feb 13. pii: 10.1007/s00277-020-03961.
    PubMed    


  166. RADUJKOVIC A, Hegenbart U, Muller-Tidow C, Herfarth K, et al
    High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience.
    Ann Hematol. 2020 Feb 8. pii: 10.1007/s00277-020-03952.
    PubMed     Abstract available


  167. CONTIERI B, Duarte BKL, Lazarini M
    Updates on DNA methylation modifiers in acute myeloid leukemia.
    Ann Hematol. 2020 Feb 6. pii: 10.1007/s00277-020-03938.
    PubMed     Abstract available


  168. KIDOGUCHI K, Yokoo M, Umino A, Aoki S, et al
    Terminal deoxynucleotidyl transferase (TdT) negative early T cell precursor acute lymphoblastic leukemia (ETP-ALL) with spontaneous acute kidney injury.
    Ann Hematol. 2020 Feb 5. pii: 10.1007/s00277-020-03943.
    PubMed    


  169. CHEN S, Li X, Ma S, Xing X, et al
    Chemogenomics analysis of drug targets for the treatment of acute promyelocytic leukemia.
    Ann Hematol. 2020 Feb 4. pii: 10.1007/s00277-019-03888.
    PubMed     Abstract available


  170. RASSIDAKIS GZ, Stromberg O, Xagoraris I, Jatta K, et al
    Trametinib and Dabrafenib in histiocytic sarcoma transdifferentiated from chronic lymphocytic leukemia with a K-RAS and a unique BRAF mutation.
    Ann Hematol. 2020 Feb 3. pii: 10.1007/s00277-020-03941.
    PubMed    


  171. OJHA S, Ooi MG
    Pregnancy exposure to midostaurin in the first trimester.
    Ann Hematol. 2020;99:355-356.
    PubMed    


  172. SIM JPY, Au-Yeung R, Kwong YL
    Low-dose pembrolizumab induced complete radiologic and molecular response of posttransplant lymphoproliferative disorder presenting as classical Hodgkin lymphoma.
    Ann Hematol. 2020;99:385-388.
    PubMed    


    January 2020
  173. HIROSAWA M, Yamaguchi T, Tanaka A, Kominato Y, et al
    Reduced-intensity haploidentical peripheral blood stem cell transplantation using low-dose thymoglobulin for aggressive adult T cell leukemia/lymphoma patients in non-complete remission.
    Ann Hematol. 2020 Jan 31. pii: 10.1007/s00277-020-03934.
    PubMed     Abstract available


  174. WANG YW, Tsai CH, Lin CC, Tien FM, et al
    Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax.
    Ann Hematol. 2020 Jan 21. pii: 10.1007/s00277-020-03911.
    PubMed     Abstract available


  175. SONG JX, Wen Y, Li RW, Dong T, et al
    Phenotypic characterization of macrophages in the BMB sample of human acute leukemia.
    Ann Hematol. 2020 Jan 18. pii: 10.1007/s00277-020-03912.
    PubMed     Abstract available


  176. LI M, Cui X, Guan H
    MicroRNAs: pivotal regulators in acute myeloid leukemia.
    Ann Hematol. 2020 Jan 13. pii: 10.1007/s00277-019-03887.
    PubMed     Abstract available


  177. FREYNET N, Tarfi S, Badaoui B, Leclerc M, et al
    Acute myelomonocytic leukemia with uncommon morphological features.
    Ann Hematol. 2020 Jan 8. pii: 10.1007/s00277-019-03883.
    PubMed    


  178. WANG XR, Chang Y, Yuan XY, Wang YZ, et al
    Overexpressed WT1 exhibits a specific immunophenotype in intermediate and poor cytogenetic risk acute myeloid leukemia.
    Ann Hematol. 2020 Jan 4. pii: 10.1007/s00277-019-03808.
    PubMed     Abstract available


    December 2019
  179. ZHANG X, Li J, Jin J, Yu W, et al
    Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.
    Ann Hematol. 2019 Dec 26. pii: 10.1007/s00277-019-03902.
    PubMed    


  180. MORI H, Sukegawa M, Fukatsu M, Sano T, et al
    The link between interleukin-1beta and acute myocardial infarction in chronic myeloid leukemia patients treated with nilotinib: cross-sectional study.
    Ann Hematol. 2019 Dec 23. pii: 10.1007/s00277-019-03896.
    PubMed    


  181. BRAVO-PEREZ C, Pajares I, Muina B, Escobar H, et al
    Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma.
    Ann Hematol. 2019 Dec 20. pii: 10.1007/s00277-019-03897.
    PubMed    


  182. PAGANO L, Maraglino AME, Fianchi L, Criscuolo M, et al
    Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT.
    Ann Hematol. 2019 Dec 12. pii: 10.1007/s00277-019-03885.
    PubMed    


  183. KHALIFE-HACHEM S, Pegliasco J, Saada V, Hernandez E, et al
    Spontaneous molecular response of IDH2 acute myeloid leukemia.
    Ann Hematol. 2019 Dec 9. pii: 10.1007/s00277-019-03876.
    PubMed    


  184. CAOCCI G, Greco M, Frau V, Asproni R, et al
    Systemic mastocytosis with associated BCRABL1-negative atypical chronic myeloid leukemia.
    Ann Hematol. 2019 Dec 6. pii: 10.1007/s00277-019-03875.
    PubMed    


  185. CHRISTIANSEN JS, Gaddh M, Wells J
    An uncommon presentation of chronic myeloid leukemia.
    Ann Hematol. 2019 Dec 2. pii: 10.1007/s00277-019-03869.
    PubMed    


  186. WANG H, Zhang N, Wu X, Zheng X, et al
    Prognostic value of U2AF1 mutant in patients with de novo myelodysplastic syndromes: a meta-analysis.
    Ann Hematol. 2019;98:2629-2639.
    PubMed     Abstract available


  187. BERGER T, Rozovski U, Moshe Y, Yaari S, et al
    Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study.
    Ann Hematol. 2019;98:2711-2717.
    PubMed     Abstract available


    November 2019
  188. KONISHI T, Doki N, Nagata A, Yamada Y, et al
    Unmanipulated haploidentical hematopoietic stem cell transplantation using very low-dose antithymocyte globulin and methylprednisolone in adults with relapsed/refractory acute leukemia.
    Ann Hematol. 2019 Nov 30. pii: 10.1007/s00277-019-03865.
    PubMed     Abstract available


  189. SUN J, Yu W, Zhang X
    MEF2D-rearranged acute lymphoblastic leukemia resembles Burkitt lymphoma/leukemia.
    Ann Hematol. 2019 Nov 28. pii: 10.1007/s00277-019-03857.
    PubMed    


  190. GAO MG, Ruan GR, Chang YJ, Liu YR, et al
    The predictive value of minimal residual disease when facing the inconsistent results detected by real-time quantitative PCR and flow cytometry in NPM1-mutated acute myeloid leukemia.
    Ann Hematol. 2019 Nov 25. pii: 10.1007/s00277-019-03861.
    PubMed     Abstract available


  191. NOGUEIRA FL, Martins NNN, Cardoso PSR, Murao M, et al
    Systemic mastocytosis associated with acute myeloid leukemia.
    Ann Hematol. 2019 Nov 25. pii: 10.1007/s00277-019-03806.
    PubMed    


  192. LIANG JH, Zhu HY, Xu DM, Wang L, et al
    A new SH2D1A mutation in a female adult XLP disease with hemophagocytic lymphohistiocytosis and NK-cell leukemia.
    Ann Hematol. 2019 Nov 22. pii: 10.1007/s00277-019-03810.
    PubMed    


  193. SALLES G, Bachy E, Smolej L, Simkovic M, et al
    Single-agent ibrutinib in RESONATE-2 and RESONATE versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
    Ann Hematol. 2019 Nov 19. pii: 10.1007/s00277-019-03830.
    PubMed     Abstract available


  194. PERI AM, Rossio R, Tafuri F, Benzecry V, et al
    Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia.
    Ann Hematol. 2019 Nov 18. pii: 10.1007/s00277-019-03837.
    PubMed    


  195. CHONABAYASHI K, Yoshida Y, Kitawaki T, Nannya Y, et al
    Acute myeloid leukemia with a cryptic NUP98/PRRX2 rearrangement developing after low-dose methotrexate therapy for rheumatoid arthritis.
    Ann Hematol. 2019 Nov 14. pii: 10.1007/s00277-019-03838.
    PubMed    


  196. BRAVO-PEREZ C, Pajares I, Muina B, Escobar H, et al
    Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma.
    Ann Hematol. 2019 Nov 11. pii: 10.1007/s00277-019-03829.
    PubMed    


  197. TIRIBELLI M, Abruzzese E, Capodanno I, Sora F, et al
    Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy.
    Ann Hematol. 2019;98:2609-2611.
    PubMed    


  198. MONTESINOS P, Bergua J, Infante J, Esteve J, et al
    Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus.
    Ann Hematol. 2019;98:2467-2483.
    PubMed     Abstract available


    October 2019
  199. ZHANG X, Jin J, Yu W
    ASXL2 mutation is recurrent in non-de novo AML1-ETO-negative acute myeloid leukemia.
    Ann Hematol. 2019 Oct 21. pii: 10.1007/s00277-019-03804.
    PubMed    


  200. WILLENBACHER E, Johrer K, Willenbacher W, Flogel B, et al
    Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia.
    Ann Hematol. 2019 Oct 18. pii: 10.1007/s00277-019-03797.
    PubMed     Abstract available


  201. ALVAREZ-LARRAN A, Lopez-Guerra M, Rozman M, Correa JG, et al
    Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis.
    Ann Hematol. 2019;98:2319-2328.
    PubMed     Abstract available


  202. CRUGNOLA M, Castagnetti F, Breccia M, Ferrero D, et al
    Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.
    Ann Hematol. 2019;98:2329-2338.
    PubMed     Abstract available


    September 2019
  203. QIN YZ, Jiang Q, Xu LP, Jiang H, et al
    The prognostic significance of Wilms' tumor gene 1 (WT1) expression at diagnosis in adults with Ph-negative B cell precursor acute lymphoblastic leukemia.
    Ann Hematol. 2019 Sep 6. pii: 10.1007/s00277-019-03789.
    PubMed     Abstract available


  204. YOUNESIAN S, Shahkarami S, Ghaffari P, Alizadeh S, et al
    Residual methylation of tumor suppressor gene promoters, RASSF6 and RASSF10, as novel biomarkers for minimal residual disease detection in adult acute lymphoblastic leukemia.
    Ann Hematol. 2019 Sep 5. pii: 10.1007/s00277-019-03775.
    PubMed     Abstract available


  205. WU X, Wang H, Deng J, Zheng X, et al
    Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis.
    Ann Hematol. 2019 Sep 3. pii: 10.1007/s00277-019-03774.
    PubMed     Abstract available


  206. CZYZEWSKI K, Styczynski J, Giebel S, Fraczkiewicz J, et al
    Age-dependent determinants of infectious complications profile in children and adults after hematopoietic cell transplantation: lesson from the nationwide study.
    Ann Hematol. 2019;98:2197-2211.
    PubMed     Abstract available


  207. WASILEWSKA E, Kuziemski K, Niedoszytko M, Kaczorowska-Hac B, et al
    Impairment of lung diffusion capacity-a new consequence in the long-term childhood leukaemia survivors.
    Ann Hematol. 2019;98:2103-2110.
    PubMed     Abstract available


    August 2019
  208. LYAPICHEV KA, Kurt H, Sukswai N, Konoplev S, et al
    Chronic lymphocytic leukemia with plasmacytic differentiation.
    Ann Hematol. 2019 Aug 26. pii: 10.1007/s00277-019-03784.
    PubMed    


  209. WU Q, Zhang R, Peng R, Fu Y, et al
    Clinician-friendly reports of molecular measurable residual disease monitoring in acute promyelocytic leukemia.
    Ann Hematol. 2019 Aug 24. pii: 10.1007/s00277-019-03782.
    PubMed     Abstract available


  210. MENDOZA H, Podoltsev NA, Siddon AJ, Gnanapandithan K, et al
    Acute myeloid leukemia presenting as bilateral adrenal hemorrhage.
    Ann Hematol. 2019 Aug 24. pii: 10.1007/s00277-019-03788.
    PubMed    


  211. NG DB, Schiller G, Ha E
    Autoimmune hemolytic anemia in refractory hairy cell leukemia on dabrafenib and trametinib.
    Ann Hematol. 2019 Aug 13. pii: 10.1007/s00277-019-03780.
    PubMed    


  212. KIDOGUCHI K, Kojima K, Yokoo M, Kimura S, et al
    BCR-ABL1- and CBFB-MYH11-positive chronic myeloid leukemia presenting with primary blast crisis and marrow fibrosis.
    Ann Hematol. 2019 Aug 10. pii: 10.1007/s00277-019-03779.
    PubMed    


  213. GIEBEL S, Boumendil A, Labopin M, Seesaghur A, et al
    Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Ann Hematol. 2019 Aug 7. pii: 10.1007/s00277-019-03771.
    PubMed     Abstract available


  214. SUN YQ, Wang Y, Zhang XH, Xu LP, et al
    Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation.
    Ann Hematol. 2019;98:1877-1883.
    PubMed     Abstract available


  215. JYOTSANA N, Sharma A, Chaturvedi A, Budida R, et al
    Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
    Ann Hematol. 2019;98:1905-1918.
    PubMed     Abstract available


  216. MULLER M, Graf R, Kashofer K, Macher S, et al
    Detection of AML-specific TP53 mutations in bone marrow-derived mesenchymal stromal cells cultured under hypoxia conditions.
    Ann Hematol. 2019;98:2019-2020.
    PubMed    


  217. MARRA A, Martino G, Ascani S, Martelli MP, et al
    Getting away with phase transition: NPM1-mutated bone myeloid sarcoma mimicking Ewing sarcoma.
    Ann Hematol. 2019;98:2017-2018.
    PubMed    


    July 2019
  218. SUH KJ, Shin DY, Kim I, Yoon SS, et al
    Comparison of quality of life and health behaviors in survivors of acute leukemia and the general population.
    Ann Hematol. 2019 Jul 23. pii: 10.1007/s00277-019-03760.
    PubMed     Abstract available


  219. YAMASAKI S, Nitta H, Kondo E, Uchida N, et al
    Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation.
    Ann Hematol. 2019 Jul 20. pii: 10.1007/s00277-019-03759.
    PubMed     Abstract available


  220. JIANG H, Liu L, Guo T, Wu Y, et al
    Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy.
    Ann Hematol. 2019;98:1721-1732.
    PubMed     Abstract available


  221. STAMOULI M, Gkirkas K, Antoniades A, Kaklamanis L, et al
    Isolated extramedullary leukemic involvement of the heart presenting as fulminant heart failure.
    Ann Hematol. 2019;98:1775-1776.
    PubMed    


    June 2019
  222. RODRIGUEZ-VEIGA R, Montesinos P, Boluda B, Lorenzo I, et al
    Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
    Ann Hematol. 2019 Jun 25. pii: 10.1007/s00277-019-03744.
    PubMed     Abstract available


  223. KAWASHIMA I, Kumagai T, Suzuki M, Suzuki J, et al
    Molecular response of CSF3R T618I harboring chronic neutrophilic leukemia after induction chemotherapy linked to cord blood transplantation.
    Ann Hematol. 2019 Jun 25. pii: 10.1007/s00277-019-03733.
    PubMed    


  224. REYES-LEON A, Ramirez-Martinez M, Fernandez-Garcia D, Amaro-Munoz D, et al
    Variants in ARID5B gene are associated with the development of acute lymphoblastic leukemia in Mexican children.
    Ann Hematol. 2019 Jun 21. pii: 10.1007/s00277-019-03730.
    PubMed     Abstract available


  225. YANADA M, Mori J, Aoki J, Masuko M, et al
    Allogeneic hematopoietic cell transplantation for patients with a history of multiple relapses of acute myeloid leukemia.
    Ann Hematol. 2019 Jun 15. pii: 10.1007/s00277-019-03736.
    PubMed     Abstract available


  226. YE P, Pei R, Jin J, Sun J, et al
    Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2019 Jun 14. pii: 10.1007/s00277-019-03723.
    PubMed     Abstract available


  227. RAM R, Amit O, Zuckerman T, Gurion R, et al
    Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
    Ann Hematol. 2019 Jun 11. pii: 10.1007/s00277-019-03719.
    PubMed     Abstract available


  228. BOASMAN K, Simmonds MJ, Graham C, Saunthararajah Y, et al
    Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation.
    Ann Hematol. 2019;98:1529-1531.
    PubMed    


  229. MCDONALD L, Fadalla K
    Synchronous follicular non-Hodgkin's lymphoma and hairy cell leukaemia: a case report.
    Ann Hematol. 2019;98:1517-1518.
    PubMed    


  230. METAFUNI E, Criscuolo M, Spanu T, Sica S, et al
    Ceftazidime-avibactam for gram-negative multidrug-resistant bacteria in hematological patients: a single-center experience.
    Ann Hematol. 2019;98:1495-1497.
    PubMed    


    May 2019
  231. REN X, Qin Y, Huang X, Zuo L, et al
    Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors.
    Ann Hematol. 2019 May 14. pii: 10.1007/s00277-019-03690.
    PubMed     Abstract available


  232. MOLICA M, Colafigli G, Scalzulli E, Alunni Fegatelli D, et al
    Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.
    Ann Hematol. 2019 May 11. pii: 10.1007/s00277-019-03706.
    PubMed     Abstract available


  233. SHIN HJ, Min WS, Min YH, Cheong JW, et al
    Different prognostic effects of core-binding factor positive AML with Korean AML registry data.
    Ann Hematol. 2019;98:1135-1147.
    PubMed     Abstract available


  234. MASHIMA K, Ikeda T, Kawaguchi SI, Toda Y, et al
    Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia.
    Ann Hematol. 2019;98:1127-1133.
    PubMed     Abstract available


  235. GARRASTAZUL-SANCHEZ MP, Vilches-Moreno M, Fernandez-Valle MC, Marchante-Cepillo I, et al
    Neutrophil faggot cells and inv(16): not such a fortuitous association?
    Ann Hematol. 2019;98:1293-1295.
    PubMed    


  236. CAOCCI G, Mulas O, Abruzzese E, Iurlo A, et al
    Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
    Ann Hematol. 2019 May 1. pii: 10.1007/s00277-019-03705.
    PubMed     Abstract available


    April 2019
  237. SU L, Gao S, Tan Y, Lin H, et al
    CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations.
    Ann Hematol. 2019 Apr 30. pii: 10.1007/s00277-019-03699.
    PubMed     Abstract available


  238. AMMATUNA E, Huls G
    Multidimensional radar dot-plots, do we need it for the screening of acute promyelocytic leukemia?
    Ann Hematol. 2019 Apr 25. pii: 10.1007/s00277-019-03693.
    PubMed    


  239. WANG Z, Yin C, Zhang W, Tang W, et al
    The benefit of chronic graft-versus-host disease in patients with acute myeloid leukemia relapsed after allogeneic stem cell transplantation.
    Ann Hematol. 2019 Apr 16. pii: 10.1007/s00277-019-03682.
    PubMed     Abstract available


  240. ZHANG X, Guo X
    Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Ann Hematol. 2019 Apr 12. pii: 10.1007/s00277-019-03674.
    PubMed    


  241. ZHANG YL, Zhu Y, Xiao Q, Wang L, et al
    Cytomegalovirus infection is associated with AML relapse after allo-HSCT: a meta-analysis of observational studies.
    Ann Hematol. 2019;98:1009-1020.
    PubMed     Abstract available


  242. BIANCHI M, Heim D, Lengerke C, Halter J, et al
    Cyclosporine levels > 195 mug/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2019;98:971-977.
    PubMed     Abstract available


  243. XHAARD A, Porcher R, Bergeron A, Alanio A, et al
    Primary antifungal prophylaxis with micafungin after allogeneic hematopoietic stem cell transplantation: a monocentric prospective study.
    Ann Hematol. 2019;98:1033-1035.
    PubMed    


    March 2019
  244. HELBIG G, Spalek A, Wieczorkiewicz-Kabut A, Markiewicz M, et al
    Allogeneic transplantation for high-risk chronic lymphocytic leukemia-a summary of a 16-year experience.
    Ann Hematol. 2019 Mar 27. pii: 10.1007/s00277-019-03679.
    PubMed     Abstract available


  245. LINS MM, Mello MJG, Ribeiro RC, De Camargo B, et al
    Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low-middle-income country.
    Ann Hematol. 2019 Mar 26. pii: 10.1007/s00277-019-03661.
    PubMed     Abstract available


  246. KONISHI T, Doki N, Kishida Y, Nagata A, et al
    Geriatric nutritional risk index (GNRI) just before allogeneic hematopoietic stem cell transplantation predicts transplant outcomes in patients older than 50 years with acute myeloid leukemia in complete remission.
    Ann Hematol. 2019 Mar 21. pii: 10.1007/s00277-019-03668.
    PubMed    


  247. KESSLER T, Koschmieder S, Schliemann C, Crysandt M, et al
    Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML).
    Ann Hematol. 2019 Mar 21. pii: 10.1007/s00277-019-03651.
    PubMed     Abstract available


  248. GAJENDRA S, Yadav AK, Chugh B, Sood N, et al
    Clinicohematologic and cytogenetic profile in a rare case of pure erythroid leukemia.
    Ann Hematol. 2019 Mar 11. pii: 10.1007/s00277-019-03660.
    PubMed    


  249. KARAI B, Habok M, Remenyi G, Rejto L, et al
    A novel flow cytometric method for enhancing acute promyelocytic leukemia screening by multidimensional dot-plots.
    Ann Hematol. 2019 Mar 4. pii: 10.1007/s00277-019-03642.
    PubMed     Abstract available


  250. KUNZ F, Kontopoulou E, Reinhardt K, Soldierer M, et al
    Detection of AML-specific mutations in pediatric patient plasma using extracellular vesicle-derived RNA.
    Ann Hematol. 2019;98:595-603.
    PubMed     Abstract available


  251. OYAKE T, Takemasa-Fujisawa Y, Sugawara N, Mine T, et al
    Doripenem versus meropenem as first-line empiric therapy of febrile neutropenia in patients with acute leukemia: a prospective, randomized study.
    Ann Hematol. 2019 Mar 1. pii: 10.1007/s00277-019-03634.
    PubMed     Abstract available


    February 2019
  252. DULUCQ S, Etienne G, Morisset S, Klein E, et al
    Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.
    Ann Hematol. 2019 Feb 23. pii: 10.1007/s00277-019-03633.
    PubMed     Abstract available


  253. YSEBAERT L, Larcher M, Compaci G, Oberic L, et al
    Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia.
    Ann Hematol. 2019 Feb 18. pii: 10.1007/s00277-019-03631.
    PubMed     Abstract available


  254. XIE W, Hu S, Xu J, Chen Z, et al
    Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults.
    Ann Hematol. 2019 Feb 13. pii: 10.1007/s00277-019-03637.
    PubMed     Abstract available


  255. GAO XN, Lin J, Wang LJ, Li F, et al
    Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
    Ann Hematol. 2019 Feb 12. pii: 10.1007/s00277-019-03636.
    PubMed     Abstract available


  256. MINA A, Shune L, Abdelhakim H, Lin TL, et al
    Long-term results of a pilot study evaluating hyperbaric oxygen therapy to improve umbilical cord blood engraftment.
    Ann Hematol. 2019;98:481-489.
    PubMed     Abstract available


  257. PICARDI M, Della Pepa R, Giordano C, Pugliese N, et al
    (1-3)-beta-D-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations.
    Ann Hematol. 2019;98:527-531.
    PubMed    


    January 2019
  258. KANAKASETTY GB, R C, K C L, Dasappa L, et al
    Treatment patterns and comparative analysis of non-intensive regimens in elderly acute myeloid leukemia patients-a real-world experience from India.
    Ann Hematol. 2019 Jan 29. pii: 10.1007/s00277-019-03600.
    PubMed     Abstract available


  259. CHEUNG E, Perissinotti AJ, Bixby DL, Burke PW, et al
    The leukemia strikes back: a review of pathogenesis and treatment of secondary AML.
    Ann Hematol. 2019 Jan 21. pii: 10.1007/s00277-019-03606.
    PubMed     Abstract available


  260. OKUYAMA S, Nito T, Yanagawa N, Tajima K, et al
    Giant cellulitis-like Sweet syndrome as an initial clinical presentation of acute myeloblastic leukemia with t(6;9)(p23;q34): DEK-CAN and internal duplications of FMS-like tyrosine kinase 3.
    Ann Hematol. 2019 Jan 18. pii: 10.1007/s00277-019-03613.
    PubMed    


  261. LIU B, Wang Y, Zhou C, Wei H, et al
    Nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center prospective study with long-term follow-up.
    Ann Hematol. 2019 Jan 11. pii: 10.1007/s00277-019-03594.
    PubMed     Abstract available


  262. LIU L, Zhang X, Qiu H, Tang X, et al
    HLA-mismatched stem cell microtransplantation compared to matched-sibling donor transplantation for intermediate/high-risk acute myeloid leukemia.
    Ann Hematol. 2019 Jan 10. pii: 10.1007/s00277-018-3583.
    PubMed     Abstract available


  263. DOPPELHAMMER M, Fraccaroli A, Prevalsek D, Bucklein V, et al
    Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis.
    Ann Hematol. 2019 Jan 8. pii: 10.1007/s00277-019-03593.
    PubMed     Abstract available


  264. STRATMANN JA, von Rose AB, Koschade S, Wendelin K, et al
    Clinical and genetic characterization of de novo double-hit B cell precursor leukemia/lymphoma.
    Ann Hematol. 2019 Jan 6. pii: 10.1007/s00277-018-03590.
    PubMed     Abstract available


  265. ZHANG Y, Zhang Y, Chen Q, Tang G, et al
    Allogeneic hematopoietic stem cells transplantation improves the survival of intermediate-risk acute myeloid leukemia patients aged less than 60 years.
    Ann Hematol. 2019 Jan 3. pii: 10.1007/s00277-018-3584.
    PubMed     Abstract available


  266. KAWASHIMA N, Akashi A, Nagata Y, Kihara R, et al
    Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.
    Ann Hematol. 2019;98:83-91.
    PubMed     Abstract available


  267. XIAOSU Z, Leqing C, Yazhen Q, Yu W, et al
    Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFbeta/MYH11 gene expression.
    Ann Hematol. 2019;98:73-81.
    PubMed     Abstract available


  268. GAO XN, Lin J, Wang SH, Huang WR, et al
    Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies.
    Ann Hematol. 2019;98:185-193.
    PubMed     Abstract available


  269. WANNER D, Bohn JP, Rudzki J, Stockhammer G, et al
    Autoimmune myelitis in a CLL patient undergoing treatment with ibrutinib.
    Ann Hematol. 2019;98:205-207.
    PubMed    


    December 2018
  270. BUCCHERI V, Barreto WG, Fogliatto LM, Capra M, et al
    Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Ann Hematol. 2018;97:2269-2278.
    PubMed     Abstract available


  271. CASTELLI R, Rossi V, Della Porta MG, Schiavon R, et al
    Clinical characteristics and treatment outcome of an 86-year-old patient with acute myeloid leukaemia with acute promyelocytic-like morphology and uncommon RARA fusion variant.
    Ann Hematol. 2018;97:2523-2525.
    PubMed    


    November 2018
  272. QASRAWI A, Bahaj W, Qasrawi L, Abughanimeh O, et al
    Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?
    Ann Hematol. 2018 Nov 23. pii: 10.1007/s00277-018-3562.
    PubMed     Abstract available


  273. ISHIDA H, Iguchi A, Aoe M, Takahashi T, et al
    Panel-based next-generation sequencing identifies prognostic and actionable genes in childhood acute lymphoblastic leukemia and is suitable for clinical sequencing.
    Ann Hematol. 2018 Nov 17. pii: 10.1007/s00277-018-3554.
    PubMed     Abstract available


  274. DE BARROS S, Vayr F, Despas F, Strumia M, et al
    The impact of chronic myeloid leukemia on employment: the French prospective study.
    Ann Hematol. 2018 Nov 17. pii: 10.1007/s00277-018-3549.
    PubMed     Abstract available


  275. GARCIA-GUTIERREZ V, Milojkovic D, Hernandez-Boluda JC, Claudiani S, et al
    Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
    Ann Hematol. 2018 Nov 16. pii: 10.1007/s00277-018-3507.
    PubMed     Abstract available


  276. PEJSA V, Lucijanic M, Jonjic Z, Prka Z, et al
    Progressive multifocal leukoencephalopathy developing after obinutuzumab treatment for chronic lymphocytic leukemia.
    Ann Hematol. 2018 Nov 13. pii: 10.1007/s00277-018-3552.
    PubMed    


  277. BODDU P, Chihara D, Masarova L, Pemmaraju N, et al
    The co-occurrence of driver mutations in chronic myeloproliferative neoplasms.
    Ann Hematol. 2018;97:2071-2080.
    PubMed     Abstract available


  278. SHALLIS RM, Xu ML, Curtis SA, Medoff E, et al
    Conviction in the face of affliction: a case series of Jehovah's Witnesses with myeloid malignancies.
    Ann Hematol. 2018;97:2245-2248.
    PubMed    


  279. BRUNELLO L, Passera R, Dellacasa CM, Giaccone L, et al
    Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients.
    Ann Hematol. 2018;97:2205-2215.
    PubMed     Abstract available


    October 2018
  280. LI Y, Shao H, Fu B
    Coexistence of t(5;17)/NPM1-RARA and t(9;22)/BCR-ABL1 in chronic myeloid leukemia at initial diagnosis.
    Ann Hematol. 2018 Oct 30. pii: 10.1007/s00277-018-3537.
    PubMed    


  281. ZAPRAZNA K, Reblova K, Svobodova V, Radova L, et al
    Activation-induced deaminase and its splice variants associate with trisomy 12 in chronic lymphocytic leukemia.
    Ann Hematol. 2018 Oct 27. pii: 10.1007/s00277-018-3520.
    PubMed     Abstract available


  282. NAKAMURA N, Ninomiya S, Matsumoto T, Nakamura H, et al
    Prognostic impact of skeletal muscle assessed by computed tomography in patients with acute myeloid leukemia.
    Ann Hematol. 2018 Oct 19. pii: 10.1007/s00277-018-3508.
    PubMed     Abstract available


  283. RANI L, Gogia A, Singh V, Kumar L, et al
    Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort.
    Ann Hematol. 2018 Oct 18. pii: 10.1007/s00277-018-3525.
    PubMed     Abstract available


  284. LEE AC, Leo SW
    Juvenile myelomonocytic leukemia: a surprising cause of peri-orbital tumor and squint.
    Ann Hematol. 2018 Oct 12. pii: 10.1007/s00277-018-3510.
    PubMed    


  285. KHALIL MMI, Messner HA, Lipton JH, Kim DD, et al
    Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies.
    Ann Hematol. 2018;97:1975-1985.
    PubMed     Abstract available


  286. EGLE A, Steurer M, Melchardt T, Weiss L, et al
    Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
    Ann Hematol. 2018;97:1825-1839.
    PubMed     Abstract available


  287. FORBRIGGER Z, Kuhle S, Brown MM, Moorehead PC, et al
    The association of venous thromboembolism with survival in pediatric cancer patients: a population-based cohort study.
    Ann Hematol. 2018;97:1903-1908.
    PubMed     Abstract available


  288. BARON F, Stevens-Kroef M, Kicinski M, Meloni G, et al
    Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials.
    Ann Hematol. 2018;97:1785-1795.
    PubMed     Abstract available


  289. BARONI F, Marraccini C, Merolle L, Piccagli V, et al
    Red blood cells metabolome changes upon treatment with different X-ray irradiation doses.
    Ann Hematol. 2018;97:1909-1917.
    PubMed     Abstract available


  290. ISOBE Y, Uemura Y, Uchida A, Miura I, et al
    A portion of expanded granular lymphocytes cause pure white cell aplasia?
    Ann Hematol. 2018;97:1995-1997.
    PubMed    


    September 2018
  291. URESHINO H, Kusaba K, Kidoguchi K, Sano H, et al
    Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma.
    Ann Hematol. 2018 Sep 27. pii: 10.1007/s00277-018-3502.
    PubMed     Abstract available


  292. JUNG SH, Lee SR, Yang DH, Lee S, et al
    Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party.
    Ann Hematol. 2018 Sep 26. pii: 10.1007/s00277-018-3495.
    PubMed     Abstract available


  293. STEIN AS, Schiller G, Benjamin R, Jia C, et al
    Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors.
    Ann Hematol. 2018 Sep 20. pii: 10.1007/s00277-018-3497.
    PubMed     Abstract available


  294. VAN DE LOUW A, Lewis AM, Yang Z
    Autopsy findings in patients with acute myeloid leukemia and non-Hodgkin lymphoma in the modern era: a focus on lung pathology and acute respiratory failure.
    Ann Hematol. 2018 Sep 14. pii: 10.1007/s00277-018-3494.
    PubMed     Abstract available


  295. ELBAEK MV, Sorensen AL, Hasselbalch HC
    Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis?
    Ann Hematol. 2018 Sep 4. pii: 10.1007/s00277-018-3489.
    PubMed     Abstract available


  296. TIMMERS NKLM, de Maar JS, van Kruijsdijk RCM, Klein SK, et al
    Central nervous system localisation of chronic lymphocytic leukaemia, description of two very distinct cases and a review of the literature.
    Ann Hematol. 2018;97:1627-1632.
    PubMed     Abstract available


  297. HATTA Y, Mizuta S, Matsuo K, Ohtake S, et al
    Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
    Ann Hematol. 2018;97:1535-1545.
    PubMed     Abstract available


    August 2018
  298. WANG H, Li Y, Lv N, Li Y, et al
    Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.
    Ann Hematol. 2018 Aug 6. pii: 10.1007/s00277-018-3464.
    PubMed     Abstract available


  299. SCHULER E, Zadrozny N, Blum S, Schroeder T, et al
    Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy.
    Ann Hematol. 2018 Aug 4. pii: 10.1007/s00277-018-3466.
    PubMed     Abstract available


  300. XIAO H, Li L, Pang Y, Wu Y, et al
    Sequential treatment combining cladribine-based re-induction, myeloablative allogeneic HSCT, and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia.
    Ann Hematol. 2018 Aug 4. pii: 10.1007/s00277-018-3453.
    PubMed     Abstract available


  301. MONTORO J, Gallur L, Merchan B, Molero A, et al
    Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes.
    Ann Hematol. 2018;97:1349-1356.
    PubMed     Abstract available


  302. DE ALVARENGA EC, Silva WN, Vasconcellos R, Paredes-Gamero EJ, et al
    Promyelocytic leukemia protein in mesenchymal stem cells is essential for leukemia progression.
    Ann Hematol. 2018 Aug 1. pii: 10.1007/s00277-018-3463.
    PubMed     Abstract available


  303. PINTO AL, Ferreira G, Carda JP, Gomes M, et al
    Isolated Richter's syndrome of the brain: diagnosis in the eye of the beholder.
    Ann Hematol. 2018;97:1509-1511.
    PubMed    


  304. CASTELLI A, Mosca-Siez ML, Riccomagno P, Patriarca A, et al
    Efficacy and safety of decitabine against cutaneous granuloblastic sarcoma: a case report.
    Ann Hematol. 2018;97:1485-1486.
    PubMed    


  305. FUREDER W, Sperr WR, Gleixner K, Thalhammer R, et al
    Major response of PNH to an AML chemotherapy protocol.
    Ann Hematol. 2018;97:1487-1488.
    PubMed    


  306. JIN Z, Xiang R, Qing K, Li X, et al
    The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
    Ann Hematol. 2018;97:1327-1335.
    PubMed     Abstract available


    July 2018
  307. SCHNEIDAWIND C, Hagmaier V, Faul C, Kanz L, et al
    Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia.
    Ann Hematol. 2018 Jul 31. pii: 10.1007/s00277-018-3454.
    PubMed     Abstract available


  308. GU B, Zhang X, Chen G, Wu X, et al
    Efficacy of haploidentical hematopoietic stem cell transplantation compared to HLA-matched transplantation for primary refractory acute myeloid leukemia.
    Ann Hematol. 2018 Jul 23. pii: 10.1007/s00277-018-3428.
    PubMed     Abstract available


  309. PARK E, Jue MS
    Radotinib-induced eruptive melanocytic nevi in patient with chronic myeloid leukemia: a case report and literature review.
    Ann Hematol. 2018 Jul 21. pii: 10.1007/s00277-018-3444.
    PubMed    


  310. BURNS TF, Loo EY, Bengtson EM, Bao L, et al
    Cytogenetically cryptic insertion of PML segment into RARA on chromosome 17q resulting PML-RARA fusion in acute promyelocytic leukemia.
    Ann Hematol. 2018 Jul 20. pii: 10.1007/s00277-018-3399.
    PubMed    


  311. ZHANG G, Zhang L, Yang X, Zhang X, et al
    High ETS2 expression predicts poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2018 Jul 18. pii: 10.1007/s00277-018-3440.
    PubMed    


  312. ZAPPASODI P, Marbello L, Borlenghi E, Fumagalli M, et al
    Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network.
    Ann Hematol. 2018 Jul 15. pii: 10.1007/s00277-018-3424.
    PubMed     Abstract available


  313. LIN XJ, Dai HP, Wang AJ, Chen F, et al
    Effects of preemptive interferon-alpha monotherapy in acute leukemia patients with relapse tendency after allogeneic hematopoietic stem cell transplantation: a case-control study.
    Ann Hematol. 2018 Jul 11. pii: 10.1007/s00277-018-3429.
    PubMed     Abstract available


  314. DUGGE R, Kreipe H, Rosenwald A, Lehmann U, et al
    Coincidence of lymphomatoid granulomatosis, chronic myelomonocytic leukemia, and anaplastic T cell lymphoma after methotrexate therapy for rheumatoid arthritis.
    Ann Hematol. 2018 Jul 7. pii: 10.1007/s00277-018-3434.
    PubMed    


  315. KONUMA T, Mizuno S, Kondo T, Yamaguchi H, et al
    Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).
    Ann Hematol. 2018 Jul 6. pii: 10.1007/s00277-018-3419.
    PubMed     Abstract available


  316. SUEDA S, Nakayama S, Adachi T, Ohashi Y, et al
    Cytotoxic T-lymphocyte-associated antigen 4-positive aggressive adult T cell leukemia/lymphoma.
    Ann Hematol. 2018 Jul 6. pii: 10.1007/s00277-018-3426.
    PubMed    


  317. MEGIAS-VERICAT JE, Martinez-Cuadron D, Sanz MA, Montesinos P, et al
    Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review.
    Ann Hematol. 2018;97:1115-1153.
    PubMed     Abstract available


  318. VANDER MEEREN S, Heyrman B, Renmans W, Bakkus M, et al
    Lymphoma-like monoclonal B cell lymphocytosis in a patient population: biology, natural evolution, and differences from CLL-like clones.
    Ann Hematol. 2018;97:1219-1227.
    PubMed     Abstract available


    June 2018
  319. KRISTON C, Plander M, Mark A, Sebestyen A, et al
    In contrast to high CD49d, low CXCR4 expression indicates the dependency of chronic lymphocytic leukemia (CLL) cells on the microenvironment.
    Ann Hematol. 2018 Jun 28. pii: 10.1007/s00277-018-3410.
    PubMed     Abstract available


  320. OSORIO S, Escudero-Vilaplana V, Gomez-Centurion I, Perez-Lopez R, et al
    Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
    Ann Hematol. 2018 Jun 28. pii: 10.1007/s00277-018-3413.
    PubMed     Abstract available


  321. KUBOTA Y, Kamachi K, Wakayama K, Kitamura H, et al
    Acute myeloid leukemia with t(19;21)(q13;q22) and marked eosinophilia.
    Ann Hematol. 2018 Jun 27. pii: 10.1007/s00277-018-3408.
    PubMed    


  322. CICCONI L, Breccia M, Franceschini L, Latagliata R, et al
    Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
    Ann Hematol. 2018 Jun 27. pii: 10.1007/s00277-018-3400.
    PubMed     Abstract available


  323. FUJIOKA I, Takaku T, Iriyama N, Tokuhira M, et al
    Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database.
    Ann Hematol. 2018 Jun 26. pii: 10.1007/s00277-018-3412.
    PubMed     Abstract available


  324. STRUGOV V, Stadnik E, Virts Y, Andreeva T, et al
    Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia.
    Ann Hematol. 2018 Jun 26. pii: 10.1007/s00277-018-3409.
    PubMed     Abstract available


  325. ZHU Y, Gao Q, Du J, Hu J, et al
    Effects of post-remission chemotherapy before allo-HSCT for acute myeloid leukemia during first complete remission: a meta-analysis.
    Ann Hematol. 2018 Jun 26. pii: 10.1007/s00277-018-3414.
    PubMed     Abstract available


  326. FEDERMANN B, Mueller MR, Steinhilber J, Horger MS, et al
    Diagnosis of Richter transformation in chronic lymphocytic leukemia: histology tips the scales.
    Ann Hematol. 2018 Jun 12. pii: 10.1007/s00277-018-3390.
    PubMed     Abstract available


  327. MAURILLO L, Buccisano F, Spagnoli A, Voso MT, et al
    Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
    Ann Hematol. 2018 Jun 10. pii: 10.1007/s00277-018-3374.
    PubMed     Abstract available


  328. LIU H, Wang SA, Schlette EJ, Xu J, et al
    Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1.
    Ann Hematol. 2018 Jun 5. pii: 10.1007/s00277-018-3389.
    PubMed     Abstract available


  329. SAKELLARI I, Gavriilaki E, Chatziioannou K, Papathanasiou M, et al
    Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study.
    Ann Hematol. 2018 Jun 5. pii: 10.1007/s00277-018-3383.
    PubMed     Abstract available


  330. SAHIN U, Dalva K, Gungor F, Ustun C, et al
    Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
    Ann Hematol. 2018;97:1027-1039.
    PubMed     Abstract available


  331. ZERKALENKOVA E, Panfyorova A, Kazakova A, Baryshev P, et al
    Molecular characteristic of acute leukemias with t(16;21)/FUS-ERG.
    Ann Hematol. 2018;97:977-988.
    PubMed     Abstract available


  332. ZHAO X, Wang Z, Ruan G, Liu Y, et al
    Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation.
    Ann Hematol. 2018;97:967-975.
    PubMed     Abstract available


  333. STRENGER V, Merth G, Lackner H, Aberle SW, et al
    Malignancy and chemotherapy induced haemophagocytic lymphohistiocytosis in children and adolescents-a single centre experience of 20 years.
    Ann Hematol. 2018;97:989-998.
    PubMed     Abstract available


  334. ZAUNER F, Tayeb S, Panagiota V, Rababah M, et al
    Acquired long QT syndrome during conditioning for allogeneic stem cell transplantation-are we aware of this side effect?
    Ann Hematol. 2018;97:1111-1113.
    PubMed    


    May 2018
  335. IWASHIGE A, Hirosawa M, Tsukada J
    Hairy cell leukemia presenting with progressive pericarditis and pleuritis.
    Ann Hematol. 2018 May 30. pii: 10.1007/s00277-018-3378.
    PubMed    


  336. MOLICA M, Scalzulli E, Colafigli G, Fegatelli DA, et al
    Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.
    Ann Hematol. 2018 May 27. pii: 10.1007/s00277-018-3375.
    PubMed     Abstract available


  337. BILL M, Grimm J, Jentzsch M, Kloss L, et al
    Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Ann Hematol. 2018 May 22. pii: 10.1007/s00277-018-3373.
    PubMed     Abstract available


  338. ALLAIN EP, Venzl K, Caron P, Turcotte V, et al
    Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients.
    Ann Hematol. 2018 May 21. pii: 10.1007/s00277-018-3356.
    PubMed     Abstract available


  339. MOLICA S, Giannarelli D, Mirabelli R, Levato L, et al
    Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis.
    Ann Hematol. 2018 May 8. pii: 10.1007/s00277-018-3350.
    PubMed    


  340. MIAO Y, Miao Y, Shi K, Sun Q, et al
    A higher percentage of cells with 13q deletion predicts worse outcome in Chinese patients with chronic lymphocytic leukemia carrying isolated 13q deletion.
    Ann Hematol. 2018 May 7. pii: 10.1007/s00277-018-3359.
    PubMed     Abstract available


  341. MARHALL A, Heidel F, Fischer T, Ronnstrand L, et al
    Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Ann Hematol. 2018;97:773-780.
    PubMed     Abstract available


  342. VIGNOLI A, Marchetti M, Falanga A
    Acute promyelocytic leukemia cell adhesion to vascular endothelium is reduced by heparins.
    Ann Hematol. 2018 May 1. pii: 10.1007/s00277-018-3343.
    PubMed     Abstract available


    April 2018
  343. HONG Y, Zhao X, Qin Y, Zhou S, et al
    The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2018 Apr 28. pii: 10.1007/s00277-018-3338.
    PubMed     Abstract available


  344. COLTOFF A, Houldsworth J, Keyzner A, Renteria AS, et al
    Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
    Ann Hematol. 2018 Apr 27. pii: 10.1007/s00277-018-3330.
    PubMed     Abstract available


  345. ZHANG J, Shi J, Zhang G, Zhang X, et al
    BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2018 Apr 25. pii: 10.1007/s00277-018-3331.
    PubMed     Abstract available


  346. ZHANG X, Li B, Yu J, Dahlstrom J, et al
    Correction to: MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.
    Ann Hematol. 2018 Apr 25. pii: 10.1007/s00277-018-3340.
    PubMed     Abstract available


  347. BRECCIA M, Abruzzese E, Castagnetti F, Bonifacio M, et al
    Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.
    Ann Hematol. 2018 Apr 19. pii: 10.1007/s00277-018-3337.
    PubMed     Abstract available


  348. WANG X, Zhang L, Zhao F, Xu R, et al
    Long non-coding RNA taurine-upregulated gene 1 correlates with poor prognosis, induces cell proliferation, and represses cell apoptosis via targeting aurora kinase A in adult acute myeloid leukemia.
    Ann Hematol. 2018 Apr 13. pii: 10.1007/s00277-018-3315.
    PubMed     Abstract available


  349. LO WJ, Lin CL, Chang YC, Bai LY, et al
    Total body irradiation tremendously impair the proliferation, differentiation and chromosomal integrity of bone marrow-derived mesenchymal stromal stem cells.
    Ann Hematol. 2018;97:697-707.
    PubMed     Abstract available


  350. SCAPPATICCI GB, Marini BL, Nachar VR, Uebel JR, et al
    Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.
    Ann Hematol. 2018;97:573-584.
    PubMed     Abstract available


    March 2018
  351. SUZUKI Y, Honda A, Nakazaki K, Mizuno H, et al
    Histological transformation of MALT lymphoma to plasma cell leukemia after rituximab-containing therapy.
    Ann Hematol. 2018 Mar 26. pii: 10.1007/s00277-018-3300.
    PubMed    


  352. SAINI NY, Bathini V
    Large granular lymphocytic leukemia-associated peripheral neuropathy.
    Ann Hematol. 2018 Mar 22. pii: 10.1007/s00277-018-3310.
    PubMed    


  353. KHAN M, Muzzafar T, Kantarjian H, Badar I, et al
    Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.
    Ann Hematol. 2018 Mar 20. pii: 10.1007/s00277-018-3289.
    PubMed     Abstract available


  354. PIATOPOULOU D, Avgeris M, Drakaki I, Marmarinos A, et al
    Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
    Ann Hematol. 2018 Mar 20. pii: 10.1007/s00277-018-3292.
    PubMed     Abstract available


  355. KIM DW, Saussele S, Williams LA, Mohamed H, et al
    Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.
    Ann Hematol. 2018 Mar 20. pii: 10.1007/s00277-018-3295.
    PubMed     Abstract available


  356. KHAN M, Siddiqi R, Naqvi K
    An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL).
    Ann Hematol. 2018 Mar 15. pii: 10.1007/s00277-018-3297.
    PubMed     Abstract available


  357. HA J, Kim B, Hahn S, Lee ST, et al
    A patient with B-cell acute lymphoblastic leukemia with PAX5-ETV6 rearrangement with dic(9;12)(p13;p13) identified by chromosomal microarray.
    Ann Hematol. 2018 Mar 8. pii: 10.1007/s00277-018-3291.
    PubMed    


  358. PARK S, Choi H, Kim HJ, Ahn JS, et al
    Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients.
    Ann Hematol. 2018 Mar 2. pii: 10.1007/s00277-018-3260.
    PubMed     Abstract available


  359. HIDALGO LOPEZ JE, Carballo-Zarate A, Verstovsek S, Wang SA, et al
    Bone marrow findings in blast phase of polycythemia vera.
    Ann Hematol. 2018;97:425-434.
    PubMed     Abstract available


  360. HARADA K, Doki N, Miyazaki Y, Wakita A, et al
    Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200.
    Ann Hematol. 2018 Mar 1. pii: 10.1007/s00277-018-3281.
    PubMed    


    February 2018
  361. MARTINEZ-CUADRON D, Boluda B, Martinez P, Bergua J, et al
    Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
    Ann Hematol. 2018 Feb 23. pii: 10.1007/s00277-018-3277.
    PubMed     Abstract available


  362. BRECCIA M, Palandri F, Luciano L, Benevolo G, et al
    Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment.
    Ann Hematol. 2018 Feb 22. pii: 10.1007/s00277-018-3258.
    PubMed     Abstract available


  363. SHIMOMURA Y, Hara M, Katoh D, Hashimoto H, et al
    Enlarged spleen is associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Ann Hematol. 2018 Feb 17. pii: 10.1007/s00277-018-3278.
    PubMed     Abstract available


  364. ZHAO HY, Song Y, Cao XN, Qin YZ, et al
    Leukemia-propagating cells demonstrate distinctive gene expression profiles compared with other cell fractions from patients with de novo Philadelphia chromosome-positive ALL.
    Ann Hematol. 2018 Feb 10. pii: 10.1007/s00277-018-3253.
    PubMed     Abstract available


  365. NAKAYAMA S, Matsuda M, Adachi T, Sueda S, et al
    Adult T cell leukemia/lymphoma with different pathological features in each tumor site.
    Ann Hematol. 2018 Feb 9. pii: 10.1007/s00277-018-3272.
    PubMed    


  366. SUZUKI Y, Koya J, Ebisawa K, Abe H, et al
    Sequential development of monoclonal B cell lymphocytosis-derived small lymphocytic lymphoma and plasma cell leukemia.
    Ann Hematol. 2018 Feb 7. pii: 10.1007/s00277-018-3248.
    PubMed    


  367. WEI G, Hu Y, Pu C, Yu J, et al
    CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study.
    Ann Hematol. 2018 Feb 7. pii: 10.1007/s00277-018-3246.
    PubMed     Abstract available


  368. DI BLASI R, Cattaneo C, Lewis RE, Tumbarello M, et al
    Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL).
    Ann Hematol. 2018 Feb 7. pii: 10.1007/s00277-018-3252.
    PubMed     Abstract available


  369. TACHIKI L, Dong ZM, Burwick N
    Atypical chronic lymphocytic leukemia presenting with massive IgM paraprotein.
    Ann Hematol. 2018 Feb 6. pii: 10.1007/s00277-018-3261.
    PubMed    


  370. MORITA K, Koya J, Toya T, Nakamura F, et al
    Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review.
    Ann Hematol. 2018 Feb 6. pii: 10.1007/s00277-018-3263.
    PubMed    


  371. FUJIMI A, Nagamachi Y, Yamauchi N
    Extramedullary involvement of the stomach presenting as multiple white elevations in the initial diagnosis of chronic myeloid leukemia treated with dasatinib.
    Ann Hematol. 2018 Feb 6. pii: 10.1007/s00277-018-3268.
    PubMed    


  372. MARTINEZ-CUADRON D, Boluda B, Martinez P, Bergua J, et al
    A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
    Ann Hematol. 2018 Feb 2. pii: 10.1007/s00277-018-3229.
    PubMed     Abstract available


  373. MELLINGHOFF SC, Panse J, Alakel N, Behre G, et al
    Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
    Ann Hematol. 2018;97:197-207.
    PubMed     Abstract available


  374. DUONG VH, Padron E, Al Ali NH, Lancet JE, et al
    The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.
    Ann Hematol. 2018;97:247-254.
    PubMed     Abstract available


  375. SCHROEDER T, Rautenberg C, Kruger W, Platzbecker U, et al
    Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Ann Hematol. 2018;97:335-342.
    PubMed     Abstract available


  376. MINODA S, Akasaka T, Okanoue Y, Honjo G, et al
    Relapse of acute promyelocytic leukemia in the external auditory canal confirmed by PML/RARA dual-fusion and RARA break-apart fluorescence in situ hybridization.
    Ann Hematol. 2018 Feb 1. pii: 10.1007/s00277-018-3235.
    PubMed    


  377. SHAHKARAMI S, Mehrasa R, Younesian S, Yaghmaie M, et al
    Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
    Ann Hematol. 2018 Feb 1. pii: 10.1007/s00277-018-3230.
    PubMed     Abstract available


  378. CHAN TSY, Kwong YL
    Systemic trichosporonosis mimicking disseminated varicella zoster viral infection during blinatumomab therapy.
    Ann Hematol. 2018;97:371-373.
    PubMed    


    January 2018
  379. SAEED OAM, Longe HO, Zhou J
    T cell large granular lymphocytic leukemia, a rare form of post lung transplant lymphoproliferative disorder.
    Ann Hematol. 2018 Jan 8. pii: 10.1007/s00277-017-3213.
    PubMed    


  380. BEN LAKHAL R, Ghedira H, Bellaaj H, Ben Youssef Y, et al
    Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
    Ann Hematol. 2018 Jan 6. pii: 10.1007/s00277-017-3224.
    PubMed     Abstract available


  381. KAMEDA K, Kako S, Hayakawa J, Akahoshi Y, et al
    Safety of avoiding systemic corticosteroid administration for grade II acute graft-versus-host disease limited to the skin.
    Ann Hematol. 2018;97:169-179.
    PubMed     Abstract available


    December 2017
  382. ZHAO H, Zhao Y, Zhang Y, Hou J, et al
    Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia.
    Ann Hematol. 2017 Dec 30. pii: 10.1007/s00277-017-3216.
    PubMed     Abstract available


  383. SADEGHI N, Li HC
    MRD-negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumab.
    Ann Hematol. 2017 Dec 28. pii: 10.1007/s00277-017-3219.
    PubMed    


  384. YANG J, Cai Y, Jiang J, Wan L, et al
    Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia.
    Ann Hematol. 2017 Dec 18. pii: 10.1007/s00277-017-3204.
    PubMed     Abstract available


  385. HARADA K, Doki N, Hagino T, Miyawaki S, et al
    Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201.
    Ann Hematol. 2017 Dec 2. pii: 10.1007/s00277-017-3156.
    PubMed     Abstract available


    November 2017
  386. HILMI M, Bally C, Burns R, Lorillon G, et al
    Favorable evolution of lung interstitial disease in a patient with chronic myelomonocytic leukemia treated with azacitidine.
    Ann Hematol. 2017 Nov 23. pii: 10.1007/s00277-017-3190.
    PubMed    


  387. HASSANI S, Khaleghian A, Ahmadian S, Alizadeh S, et al
    Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4).
    Ann Hematol. 2017 Nov 20. doi: 10.1007/s00277-017-3163.
    PubMed     Abstract available


  388. PRATS-MARTIN C, Jimenez-Guerrero P, Morales-Camacho RM, Caballero-Velazquez T, et al
    KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2017 Nov 18. doi: 10.1007/s00277-017-3187.
    PubMed    


  389. SHAO H, Yang Q, Zhang P, Liu H, et al
    Simultaneous occurrence of two distinct leukemic clones with PML-RARalpha and RUNX1-RUNX1T1 in a case of acute myeloid leukemia.
    Ann Hematol. 2017 Nov 9. doi: 10.1007/s00277-017-3169.
    PubMed    


  390. LORENZANA N, Avila LF, Alonso S, Colado E, et al
    The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment.
    Ann Hematol. 2017;96:1833-1840.
    PubMed     Abstract available


    October 2017
  391. NASSEREDDINE S, Lap CJ, Haroun F, Tabbara I, et al
    The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
    Ann Hematol. 2017 Oct 31. doi: 10.1007/s00277-017-3161.
    PubMed     Abstract available


  392. NAGEL G, Weber D, Fromm E, Erhardt S, et al
    Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).
    Ann Hematol. 2017 Oct 31. doi: 10.1007/s00277-017-3150.
    PubMed     Abstract available


  393. YANG D, Zhang X, Zhang X, Xu Y, et al
    The progress and current status of immunotherapy in acute myeloid leukemia.
    Ann Hematol. 2017 Oct 28. doi: 10.1007/s00277-017-3148.
    PubMed     Abstract available


  394. ZHANG X, Li B, Yu J, Dahlstrom J, et al
    MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.
    Ann Hematol. 2017 Oct 27. doi: 10.1007/s00277-017-3158.
    PubMed     Abstract available


  395. KHAN M, Siddiqi R, Thompson PA
    Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies.
    Ann Hematol. 2017 Oct 23. doi: 10.1007/s00277-017-3149.
    PubMed     Abstract available


  396. GUTIERREZ-AGUIRRE CH, Flores-Jimenez JA, Alatorre-Ricardo J, Cantu-Rodriguez OG, et al
    The prognostic significance of serum XCL1 concentration in patients with acute lymphoblastic leukemia: a pilot study.
    Ann Hematol. 2017 Oct 13. doi: 10.1007/s00277-017-3142.
    PubMed     Abstract available


  397. TERADA K, Yamaguchi H, Ueki T, Usuki K, et al
    Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor.
    Ann Hematol. 2017 Oct 4. doi: 10.1007/s00277-017-3143.
    PubMed     Abstract available


  398. IURLO A, Galimberti S, Abruzzese E, Annunziata M, et al
    Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.
    Ann Hematol. 2017 Oct 2. doi: 10.1007/s00277-017-3144.
    PubMed     Abstract available


  399. YANAGIHARA T, Ikematsu Y, Kato K, Yonekawa A, et al
    Expression of PD-1 and PD-L1 on cytotoxic T lymphocytes and immune deficiency in a patient with adult T cell leukemia/lymphoma.
    Ann Hematol. 2017 Oct 2. doi: 10.1007/s00277-017-3146.
    PubMed    


  400. SAMADI O, Breunis H, Sandoval J, Akilan K, et al
    Return to work and work-related disability among AML survivors.
    Ann Hematol. 2017;96:1625-1633.
    PubMed     Abstract available


  401. HANSSON L, Asklid A, Diels J, Eketorp-Sylvan S, et al
    Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia.
    Ann Hematol. 2017;96:1681-1691.
    PubMed     Abstract available


  402. HAMADOU WS, Mani R, Besbes S, Bourdon V, et al
    GATA2 gene analysis in several forms of hematological malignancies including familial aggregations.
    Ann Hematol. 2017;96:1635-1639.
    PubMed     Abstract available


    September 2017
  403. HOU J, Wang S, Zhang Y, Fan D, et al
    Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.
    Ann Hematol. 2017 Sep 22. doi: 10.1007/s00277-017-3130.
    PubMed     Abstract available


  404. JAWHAR M, Naumann N, Schwaab J, Baurmann H, et al
    Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.
    Ann Hematol. 2017;96:1463-1470.
    PubMed     Abstract available


  405. HAROUN F, Solola SA, Nassereddine S, Tabbara I, et al
    PD-1 signaling and inhibition in AML and MDS.
    Ann Hematol. 2017;96:1441-1448.
    PubMed     Abstract available


    August 2017
  406. SHAO H, Yang Q, Wu C, Cen J, et al
    Therapy-related acute myeloid leukemia with inv(16) after successful therapy for de novo acute myeloid leukemia with t(8;21).
    Ann Hematol. 2017 Aug 24. doi: 10.1007/s00277-017-3110.
    PubMed    


  407. OH SB, Park SW, Chung JS, Lee WS, et al
    Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.
    Ann Hematol. 2017 Aug 21. doi: 10.1007/s00277-017-3104.
    PubMed     Abstract available


  408. IURLO A, Bucelli C, Cattaneo D, Orofino N, et al
    Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia.
    Ann Hematol. 2017 Aug 19. doi: 10.1007/s00277-017-3105.
    PubMed    


  409. LOU Y, Ma Y, Sun J, Suo S, et al
    Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia.
    Ann Hematol. 2017 Aug 19. doi: 10.1007/s00277-017-3096.
    PubMed     Abstract available


  410. ZHAO Y, Wang J, Luo Y, Shi J, et al
    Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.
    Ann Hematol. 2017;96:1353-1360.
    PubMed     Abstract available


  411. SAGLIO G, le Coutre P, Cortes J, Mayer J, et al
    Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.
    Ann Hematol. 2017;96:1303-1313.
    PubMed     Abstract available


  412. EREN R, Dogu MH, Emir S, Huq GE, et al
    Rethinking the usefulness of bone marrow biopsy on treatment decision in CLL patients at diagnosis.
    Ann Hematol. 2017;96:1315-1321.
    PubMed     Abstract available


    July 2017
  413. YUI S, Kurosawa S, Yamaguchi H, Kanamori H, et al
    D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.
    Ann Hematol. 2017 Jul 31. doi: 10.1007/s00277-017-3074.
    PubMed     Abstract available


  414. NISCOLA P, Tendas A, Abruzzese E, Caravita T, et al
    Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice.
    Ann Hematol. 2017 Jul 12. doi: 10.1007/s00277-017-3064.
    PubMed    


  415. THOMAY K, Fedder C, Hofmann W, Kreipe H, et al
    Telomere shortening, TP53 mutations and deletions in chronic lymphocytic leukemia result in increased chromosomal instability and breakpoint clustering in heterochromatic regions.
    Ann Hematol. 2017 Jul 9. doi: 10.1007/s00277-017-3055.
    PubMed     Abstract available


  416. VENTURA FERREIRA MS, Crysandt M, Ziegler P, Hummel S, et al
    Evidence for a pre-existing telomere deficit in non-clonal hematopoietic stem cells in patients with acute myeloid leukemia.
    Ann Hematol. 2017 Jul 3. doi: 10.1007/s00277-017-3049.
    PubMed     Abstract available


  417. RODRIGUEZ-VEIGA R, Igual B, Montesinos P, Tormo M, et al
    Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin.
    Ann Hematol. 2017;96:1077-1084.
    PubMed     Abstract available


  418. KAUR V, Swami A
    Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
    Ann Hematol. 2017;96:1175-1184.
    PubMed     Abstract available


    June 2017
  419. URESHINO H, Kamachi K, Miyahara M
    Detection of human T-cell lymphotropic virus type I-specific cytotoxic T-cells may predict treatment responses in adult T-cell leukemia/lymphoma patients.
    Ann Hematol. 2017 Jun 27. doi: 10.1007/s00277-017-3052.
    PubMed    


  420. BALDUCCI E, Nivaggioni V, Boudjarane J, Bouriche L, et al
    Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy.
    Ann Hematol. 2017 Jun 20. doi: 10.1007/s00277-017-3050.
    PubMed    


  421. HEUSER M, Gabdoulline R, Loffeld P, Dobbernack V, et al
    Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2017 Jun 13. doi: 10.1007/s00277-017-3027.
    PubMed     Abstract available


  422. JONSSON S, Olsson B, Soderberg J, Wadenvik H, et al
    Erratum to: Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study.
    Ann Hematol. 2017 Jun 9. doi: 10.1007/s00277-017-3024.
    PubMed    


  423. DE LACERDA MP, Guedes NR, Yamakawa PE, Pereira AD, et al
    Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with (del17p).
    Ann Hematol. 2017 Jun 9. doi: 10.1007/s00277-017-3039.
    PubMed    


  424. ABLA O, Ribeiro RC, Testi AM, Montesinos P, et al
    Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy.
    Ann Hematol. 2017 Jun 8. doi: 10.1007/s00277-017-3042.
    PubMed     Abstract available


  425. MUKHERJEE S, Ibrahimi S, John S, Adnan MM, et al
    Non-seminomatous mediastinal germ cell tumor and acute megakaryoblastic leukemia.
    Ann Hematol. 2017 Jun 3. doi: 10.1007/s00277-017-3037.
    PubMed     Abstract available


  426. OKA S, Ono K, Nohgawa M
    Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation.
    Ann Hematol. 2017 Jun 2. doi: 10.1007/s00277-017-3032.
    PubMed    


  427. BRAULKE F, Schulz X, Germing U, Schuler E, et al
    Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.
    Ann Hematol. 2017;96:887-894.
    PubMed     Abstract available


  428. CHOI DC, Tremblay D, Iancu-Rubin C, Mascarenhas J, et al
    Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.
    Ann Hematol. 2017;96:919-927.
    PubMed     Abstract available


    May 2017
  429. GONG Z, Zheng L, Tang Z, Chen Z, et al
    Erratum to: Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Ann Hematol. 2017 May 20. doi: 10.1007/s00277-017-3025.
    PubMed    


  430. HAEN SP, Groh C, Schumm M, Backert L, et al
    Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation.
    Ann Hematol. 2017;96:817-827.
    PubMed     Abstract available


    April 2017
  431. MATERN S, Schmidt E, Hartmann D, Schliemann C, et al
    Successful second allogeneic stem cell transplantation in a patient with T-lymphoblastic leukemia (T-ALL) relapsed as myeloid sarcoma.
    Ann Hematol. 2017 Apr 27. doi: 10.1007/s00277-017-3000.
    PubMed    


  432. SANCHEZ R, Ayala R, Alonso RA, Martinez MP, et al
    Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid.
    Ann Hematol. 2017 Apr 27. doi: 10.1007/s00277-017-3002.
    PubMed     Abstract available


  433. KOYA J, Ibaraki T, Yamazaki I, Nakamura F, et al
    Acute basophilic leukemia with add(3)(q12) accompanied by histamine excess symptoms.
    Ann Hematol. 2017 Apr 19. doi: 10.1007/s00277-017-2987.
    PubMed    


  434. ESPINOSA LARA P, Quiros Redondo V, Aguado Lobo M, Jimenez-Reyes J, et al
    Purpuric exanthema in a patient with hairy cell leukemia treated with cladribine and allopurinol.
    Ann Hematol. 2017 Apr 8. doi: 10.1007/s00277-017-2992.
    PubMed    


  435. SHUSTIK C, Bence-Bruckler I, Delage R, Owen CJ, et al
    Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
    Ann Hematol. 2017 Apr 7. doi: 10.1007/s00277-017-2982.
    PubMed     Abstract available


    March 2017
  436. DUNOYER-GEINDRE S, Rivier-Cordey AS, Tsopra O, Lecompte T, et al
    Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1beta.
    Ann Hematol. 2017 Mar 25. doi: 10.1007/s00277-017-2970.
    PubMed     Abstract available


  437. BOTH A, Krauter J, Damm F, Thol F, et al
    The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia.
    Ann Hematol. 2017 Mar 22. doi: 10.1007/s00277-017-2967.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: